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PREMESSA 
______________________________________________________________________ 
 
 
L’epatopatia steatosica non alcolica (non-alcoholic fatty liver disease, NAFLD) si 
riferisce ad uno spettro di quadri clinici che vanno dalla steatosi semplice alla steatosi 
con aspetti necro-infiammatori (steatoepatite), alla fibrosi e infine alla cirrosi, e 
rappresenta una delle più comuni patologie epatiche nei paesi occidentali (Farrell and 
Larter, 2006). Dai dati scientifici recentemente pubblicati emerge che lo stadio di cirrosi 
può richiedere un trapianto di fegato ed è associato in maniera rilevante al rischio di 
sviluppo del carcinoma epatocellulare (hepatocellular carcinoma, HCC) (Jiang and 
Torok, 2008). E’ opportuno mettere in evidenza che la NAFLD è presente non solo 
negli adulti, ma sono in aumento le diagnosi nei pazienti in età pediatrica. Secondo le 
previsioni dell’Organizzazione Mondiale della Sanità (World Health Organization, 
WHO), almeno 2 milioni di persone svilupperanno la cirrosi come conseguenza della 
steatosi epatica e la NAFLD diventerà la causa principale di trapianti di fegato nei 
prossimi decenni (Schreuder et al., 2008). Per questo motivo, la steatosi epatica non 
dovrebbe essere considerata come una condizione innocua, ma piuttosto come un 
importante fattore di rischio con un potenziale evolutivo verso patologie epatiche più 
avanzate (den Boer et al., 2004; Bradbury, 2006). Purtroppo, fino ad ora nessun 
trattamento specifico per i pazienti colpiti dalla NAFLD si è dimostrato completamente 
efficace (Schreuder et al., 2008). 
Negli ultimi anni, una notevole attenzione è stata indirizzata sui recettori nucleari come 
possibili bersagli di farmaci nella terapia farmacologia (Tobin and Freedman, 2006). 
Alcuni membri della superfamiglia dei recettori nucleari [p.es. peroxisome proliferator-
activated receptors (PPARs), constitutive androstane receptor (CAR), liver X receptor 
(LXR), farnesoid X receptor (FXR), pregnane X receptor (PXR)] che fungono da fattori 
trascrizionali, funzionano come sensori intracellulari dei metaboliti del colesterolo, 
degli acidi grassi e delle molecole lipofiliche con un ruolo fondamentale nell’omeostasi 
energetica, nel metabolismo lipidico e nell’infiammazione (George and Liddle, 2007). 
Sino ad oggi, soltanto gli agonisti PPARγ (tiazolidinedioni) e PPARα (clofibrato) sono 
stati testati in studi pilota su pazienti umani (Laurin et al., 1996; Miyazaki et al., 2002; 
Neuschwander-Tetri et al., 2003a; Sanyal et al., 2004; Belfort et al., 2006). Tuttavia, la 
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scoperta di rilevanti effetti collaterali derivanti dall’utilizzo di questa classe di farmaci 
ha stimolato ulteriori ricerche nel campo dei recettori nucleari mediante l’uso sia di 
modelli cellulari che animali (George and Liddle, 2007). 
I processi correlati al metabolismo dei lipidi e del colesterolo sono influenzati anche 
dagli ormoni tiroidei, in particolare dalla triiodotironina (T3). Suscita interesse il fatto 
che l’attività biologica del T3 deriva dall’attivazione dei recettori per gli ormoni tiroidei 
che appartengono alla suddetta superfamiglia dei recettori nucleari. Il potenziale 
terapeutico degli agonisti del recettore dell’ormone tiroideo, come gli agenti in grado di 
ridurre il peso corporeo e i lipidi ematici, è stato a lungo l’obiettivo della ricerca 
(Moreno et al., 2008). Tuttavia, l’ipotetico effetto del T3 sulla NAFLD rimane ancora 
largamente inesplorato. 
Di conseguenza, ci è sembrato di notevole interesse esaminare quest’ipotesi. Lo scopo 
di questa tesi, quindi, è stato quello di valutare l’effetto del T3 e di un analogo 
strutturale del recettore dell’ormone tiroideo sulla steatosi epatica. 
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The term non-alcoholic fatty liver disease (NAFLD) has been used as a general name 
for conditions ranging from simple steatosis to steatohepatitis, advanced fibrosis and 
cirrhosis. NAFLD, present in up to one-third of the general population with a very high 
prevalence in North and South America, Asia-Pacific (including Australia and New 
Zealand), the Middle East and Europe, is emerging as one of the most common liver 
diseases (Farrell and Larter, 2006). Newly published scientific data demonstrate that 
end-stage NAFLD cirrhosis may require liver transplantation and carries a substantial 
risk for early hepatocellular carcinoma (HCC) development (Jiang and Torok, 2008). 
Worryingly, NAFLD is also reported increasingly in paediatric patients. According to 
the World Health Organization (WHO) predictions, at least two million people will 
develop cirrhosis due to hepatic steatosis and NAFLD will become the leading 
indication for liver transplantation in the next decades (Schreuder et al., 2008). In this 
respect, the awareness and the importance of diagnosing this alarming entity should be 
emphasized. Furthermore, it becomes evident that hepatic steatosis should not be 
regarded as an innocuous, benign condition, even in its bland form, but rather as a 
growing public health concern and an important cause of advanced liver disease (den 
Boer et al., 2004; Bradbury, 2006). Up till now, no exact treatment strategy for patients 
suffering from NAFLD has been conclusively proved to be effective (Schreuder et al., 
2008). 
Recently, considerable interest has been focused on nuclear receptors as attractive drug 
targets for the management of NAFLD (Tobin and Freedman, 2006). Some members of 
the large superfamily of nuclear hormone receptors [e.g. peroxisome proliferator-
activated receptors (PPARs), constitutive androstane receptor (CAR), liver X receptor 
(LXR), farnesoid X receptor (FXR), pregnane X receptor (PXR)] which function as 
ligand-activated transcription factors, are known to act as intracellular sensors for 
cholesterol metabolites, free fatty acids, and a range of other lipophilic molecules with 
critical roles in energy homeostasis, lipid metabolism and inflammation (George and 
Liddle, 2007). To date, only PPARγ (thiazolidinediones: troglitazone, rosiglitazone and 
pioglitazone) and PPARα (clofibrate) agonists have been investigated in human pilot 
studies (Laurin et al., 1996; Miyazaki et al., 2002; Neuschwander-Tetri et al., 2003a; 
Sanyal et al., 2004; Belfort et al., 2006). However, it has been discovered that these 
drugs have significant side effects, so alternate approaches to nuclear receptor targeting 
are being explored in animal- or cell-based models (George and Liddle, 2007). 
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The processes and pathways related to lipid and cholesterol handling are also affected 
by thyroid hormones (THs), in particular triiodothyronine (T3). Interestingly, biological 
activity of T3 arises from activation of TH receptors (TRs) which are members of the 
abovementioned superfamily of nuclear hormone receptors. The therapeutic potential of 
thyroid hormone receptor agonists as lipid- and weight-lowering agents has long been 
the focus of research (Moreno et al., 2008). However, the hypothetical effect of T3 on 
NAFLD remained largely unexplored. 
Consequently, it seemed to us particularly noteworthy to broaden this concept and the 
aim of this dissertation was to examine the influence of T3 and TH structural analog on 
fatty liver disease. 
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INTRODUCTION 
______________________________________________________________________ 
 
Lipid flux in the liver and hepatic steatosis 
 
The liver is a central player in the whole body energy homeostasis by its ability to store 
glucose in the form of glycogen and distribute fuel sources (glucose and lipids) to 
peripheral tissues. It is also known to be a major regulator of metabolite flow in the 
body (Reddy and Rao, 2006) and to play a fundamental role in lipid metabolism through 
(Fig. 1): 
• the uptake of fatty acids; 
• fatty acid oxidation; 
• de novo fatty acid synthesis, a key metabolic pathway for energy homeostasis in 
higher animals; 
• assembly and secretion of very low density lipoprotein-triglyceride (VLDL-TG); 
• effects of fatty acids on gene expression by controlling the activity or abundance 
of key transcription factors (den Boer et al., 2004; Jump et al., 2005). 
 
 
 
Fig. 1. Major pathways of hepatic fatty acid/triglyceride metabolism in the liver (den 
Boer et al., 2004). 
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Lipids arrive at the hepatocyte surface in a number of forms, but an important source is 
represented by circulating free fatty acids (FFAs), deriving from lipolysis of stored TGs 
in adipocytes and dietary fat. FFAs are energy-rich molecules that are pivotal for a 
variety of cellular processes including energy storage, synthesis of cellular membranes, 
and generation of lipid-containing messengers in signal transduction (Reddy, 2001). 
Both liver and adipose tissue play a crucial role during free fatty acid metabolism and 
transportation. As evident from Figure 2, lipoprotein lipase (LPL) on adipocytes 
releases FFA from lipoprotein particles. The FFA is subsequently transported into the 
adipocyte and then esterified to TG for storage. Successively, stored TG undergoes 
lipolysis by hormone-sensitive lipase (HSL) to produce FFA for export into the plasma. 
At the hepatocyte, hepatic lipase (HL) produces FFA from lipoproteins which is 
transported into the hepatocyte along with plasma FFA. Within the liver, FFA either 
enter mitochondria to undergo oxidation as fuel or is esterified to TG (a storage form of 
three long-chain fatty acids bound to glycerol backbone by ester bonds) (Bradbury, 
2006). 
 
 
 
Fig. 2. Free fatty acid metabolism and transport (Bradbury, 2006). 
 
Subsequently, depending on the availability, TGs can be stored in lipid droplets for later 
use or secreted into the blood in the form of VLDL-TG particles and directed toward 
different tissues. Plasma VLDL-TG particles consist of TGs droplets (and cholesterol 
esters) surrounded by phospholipids and a large glycoprotein named apolipoprotein B 
(apoB) (Begriche et al., 2006). The assembly of apoB into VLDL is a complex process, 
divided into two steps. Briefly, in the first step, apoB is co-translationally lipidated in 
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the rough endoplasmic reticulum by microsomal triglyceride transfer protein (MTP) 
(Fig. 3, step 1-4). The second process includes fusion of apoB-containing precursor 
particles with TGs droplets to form mature VLDL-TG (Fig. 3, step 5-6). Fully lipidated 
apoB molecules migrate to the sinusoidal membrane of the hepatocyte and fuse with the 
membrane to be secreted into blood (Shelness and Sellers, 2001). 
 
 
 
Fig. 3. Domain structure of apoB and VLDL-TG assembly (Shelness and Sellers, 2001). 
 
Despite the complexity and a high degree of coordination of the liver lipid machinery, 
the overflow of any metabolite pool can lead to organ function impairment and 
subsequent pathologies (Nguyen et al., 2008). For example, the TG content of 
hepatocytes is regulated by the integrated activities of cellular molecules that facilitate 
hepatic TG uptake, fatty acid synthesis and esterification on one hand (‘‘input’’) and 
hepatic fatty acid oxidation and TG export on the other (‘‘output’’). However, when 
‘‘input’’ exceeds the capacity for ‘‘output’’, hepatic steatosis occurs. Its hallmark 
feature is the presence of significant amounts of TGs in hepatocytes (den Boer et al., 
2004). Sources of excess accumulation of triglycerides within the liver result from 
defects in any one of the events in the sequence from fatty acid entry to lipoprotein exit 
and may include: 
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 increased fatty acid influx into the liver from lipolysis of adipose tissue and 
subsequent conversion to TG; 
 increased TG synthesis from elevated de novo synthesis of fatty acids; 
 excess dietary TG associated with overeating that reach the liver as 
chylomicron particles from the intestine; 
 reduced fatty acid oxidation; 
 impaired VLDL-TG synthesis or secretion (Reddy and Rao, 2006; Anderson 
and Borlak, 2008). 
Two major histological patterns of fat droplets accumulation in the liver parenchymal 
cells are defined. Macrovesicular hepatic steatosis manifests as an accumulation of large 
lipid vacuole filling the hepatocyte cytoplasm, resulting in peripheral displacement of 
the nucleus, whereas microvesicular steatosis is characterised by the presence of 
numerous small fat droplets without displacing the nucleus to the periphery. There are 
different causes which lead to these two morphological types of steatosis. 
Macrovesicular steatosis is related to alcoholic, obese and diabetic states as well as 
certain malnutrition states, such as Kwashiorkor syndrome and may manifest in zone 3 
(of the liver) or may present as panacinar with increasing severity. On the contrary, 
genetic or toxin-induced abnormalities in mitochondrial and peroxisomal β-oxidation of 
fatty acids cause microvesicular hepatic steatosis. This type tends also to be rapidly 
progressive and more severe (Reddy and Rao, 2006). 
 
Non-alcoholic fatty liver disease: from steatosis to cirrhosis 
 
Since 1845, when alcohol-induced liver steatosis was first described, the majority of 
cases of fatty liver disease (FLD) was attributed to the excessive use of alcohol. 
Throughout the recent years, research on non-alcoholic causes of FLD, diagnosed in 
individuals whose alcohol consumption was nil or negligible, increased exponentially 
and attracted considerable attention. As a consequence, FLD is now clinically 
categorized into two broad entities: alcoholic FLD and non-alcoholic FLD (Farrell and 
Larter, 2006; Reddy and Rao, 2006). The embracing term non-alcoholic fatty liver 
disease (NAFLD) has been adopted to cover the full spectrum of metabolic fatty 
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disorders, ranging from simple steatosis to steatohepatitis, advanced fibrosis and 
cirrhosis. The acronym NASH (non-alcoholic steatohepatitis), coined by Ludwig to 
describe a liver disease that histologically mimics alcoholic hepatitis but occurs without 
abuse of alcohol, refers to a stage within the spectrum of NAFLD (Das and Kar, 2005; 
Ota et al., 2007). In the past, histological characteristics of NASH used to be 
controversial and varied in the literature. As recently proposed (Neuschwander-Tetri et 
al., 2003b), the histopathological features of non-alcoholic steatohepatitis encompass 
zone 3 predominate macrovesicular steatosis in combination with hepatocyte ballooning 
and a mixed inflammatory infiltrate often with characteristic perisinusoidal and 
pericellular fibrosis. Despite the high prevalence of NAFLD and its potential for serious 
sequelae, the underlying etiologic factors that determine disease progression are poorly 
understood (Farrell and Larter, 2006). Metabolic studies in humans and animals show 
inextricable association with insulin resistance and features of the metabolic syndrome. 
Over 90% of patients with NAFLD represent at least one feature of metabolic 
syndrome. As lately published (Ota et al., 2007), diabetes or insulin resistance may 
accelerate the entire pathological spectrum of NAFLD. Less commonly, NAFLD may 
be a result of secondary causes such as medications (e.g. corticosteroids, tamoxifen), 
nutritional causes (e.g. rapid weight loss) or metabolic diseases (e.g. lipodystrophy or 
dysbetalipoproteinaemia) (Adams and Angulo, 2005; Adams et al., 2005). Remarkably, 
NAFLD if often diagnosed in asymptomatic persons after the detection of raised 
aminotransferases at a routine check-up or abnormal hepatic ultrasonography made for 
another purpose (e.g. suspicion of biliary disease). Even if alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) values are elevated in many cases, 
transaminases in the normal range, despite histologically significant disease, are also 
observed. Moreover, the presence of symptoms, usually non specific, does not appear 
reliably related to disease severity. Although pharmacological therapy has elicited 
considerable interest and different classes of drugs have been examined in human pilot 
studies (e.g. antioxidants, ursodeoxycholic acid, metformin, lipid lowering drugs), up 
till now, no accepted treatment strategy for patients suffering from NAFLD has been 
well established (Farrell and Larter, 2006). Taken all together, many issues remain 
unresolved regarding the diagnosis and treatment of NAFLD (Neuschwander-Tetri et 
al., 2003b). 
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Nuclear receptors as drug targets in NAFLD 
 
In recent years, the significance of nuclear receptors as attractive drug targets for the 
management of metabolic diseases has been emphasized (Tobin and Freedman, 2006; 
George and Liddle, 2007). Some members of the large superfamily of nuclear hormone 
receptors [e.g. peroxisome proliferator-activated receptors (PPARs), constitutive 
androstane receptor (CAR), liver X receptor (LXR), farnesoid X receptor (FXR), 
pregnane X receptor (PXR)] which function as ligand-activated transcription factors, are 
known to act as intracellular sensors for cholesterol metabolites, free fatty acids, and a 
range of other lipophilic molecules with critical roles in energy homeostasis, lipid 
metabolism and inflammation (George and Liddle, 2007). For example, involvement of 
PPARs in the development of hepatic steatosis and inflammation has been extensively 
characterized. The PPAR family of transcription factors encompasses three members: 
PPARα, PPARδ and PPARγ. First of all, using a nutritional model of non-alcoholic 
steatohepatitis in PPARα-
-/-
 mice demonstrated that these animals display severe hepatic 
steatosis, elevated serum cholesterol and TG levels, as well as reduced capacity to 
metabolize fatty acids (Linden et al., 2001; Kashireddy and Rao, 2004a). Secondly, it 
has been shown that ligand-activation of PPARα, acting as a molecular sensor of 
endogenous fatty acids and their derivates, regulates the expression of genes encoding 
enzymes and transport proteins controlling lipid homeostasis, thereby stimulating β-
oxidation of fatty acids and improving lipoprotein metabolism. Moreover, PPARα 
activation has anti-inflammatory effects via inhibition of cyclooxygenase-2 (COX-2) 
and interleukin-6 (IL-6) (Lefebvre et al., 2006; George and Liddle, 2007). It has been 
also observed that ciprofibrate, a potent PPARα ligand, is able not only to prevent but 
also to reverse the development of the dietary-induced steatohepatitis and normalize 
serum aminotransferases (Rao et al., 2002). In another report, a potent and selective 
synthetic PPARδ-agonist, GW501516, demonstrated similar protective effect improving 
hepatic steatosis. This receptor has been also indicated as a therapeutic target for the 
treatment of multiple components of the metabolic syndrome (e.g. obesity, 
hyperglycemia, insulin resistance, dyslipidemia). Furthermore, also PPARγ agonists 
seem an attractive therapeutic option as the overall effect of PPARγ activation include 
an increase in insulin sensitivity and glycemic control. This event is accompanied by a 
reduction in circulating free fatty acids (Tobin and Freedman, 2006). Additionally, 
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PPARγ appears to be involved in the maintenance of a quiescent phenotype of hepatic 
stellate cells, the characteristic relevant to the prevention of liver fibrogenesis (Marra et 
al., 2000). To date, PPARα (clofibrate) and PPARγ (thiazolidinediones: troglitazone, 
rosiglitazone and pioglitazone) agonists have been investigated in human pilot studies 
(Laurin et al., 1996; Miyazaki et al., 2002; Neuschwander-Tetri et al., 2003a; Sanyal et 
al., 2004; Belfort et al., 2006). However, it has been revealed that these drugs have 
potential adverse effects. Therefore, the need for further research on larger randomized 
controlled trials has been underlined (George and Liddle, 2007). 
Other nuclear receptors have only recently begun to be examined for their role in the 
pathogenesis or treatment of NAFLD. Similar effect to that of ligands of the PPARs has 
been observed with 1,4-bis-[2-(3,5-dichloropyridoloxy)]benzene (TCPOBOP), a ligand 
of constitutive androstane receptor (CAR) (a biosensor for endo- and xenobiotic 
compounds), another member of the nuclear receptor superfamily. It has been reported 
that activation of CAR by TCPOBOP reduced hepatic steatosis, serum triglyceride 
levels and was sufficient to attenuate inflammation in a rodent nutritional model of 
NASH (Baskin-Bey et al., 2007). 
Although 3,5,3’-triiodo-L-thyronine (T3), an agonist of another member of the 
steroid/thyroid hormone nuclear receptor superfamily (Germain et al., 2006), resembles 
peroxisome proliferators (PPs), ligands of the PPARs, as well as CAR agonists, 
regulating serum lipid homeostasis and fat tissue metabolism (Castellan et al., 1991; 
Hulbert, 2000), and being a potent hepatomitogen (Pibiri et al., 2001; Ledda-
Columbano et al., 2003), its hypothetical effect on NAFLD remained largely 
unexplored. 
 
Molecular basis of thyroid hormone action 
 
The thyroid gland, whose biological importance has been recognized for centuries, 
produces 3,5,3’,5’-tetraiodo-L-thyronine (T4) and 3,5,3’-triiodo-L-thyronine (T3) which 
affect numerous physiological processes (Lazar, 2003). Not only do thyroid hormones 
(THs) play a critical role during embryogenesis and postnatal growth (they are essential 
for endochondral bone formation) but also have profound influence in adult life, 
affecting the processes and pathways related to lipid and cholesterol handling as well as, 
mediating protein, carbohydrate and vitamin metabolism. Among the pleiotropic effects 
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exerted by THs we can also mention their influence on metamorphosis in amphibians 
and development of the vertebrate nervous system (Moreno et al., 2008). A negative 
feedback system involving hypothalamus, pituitary and thyroid gland 
(hypothalamus/pituitary/thyroid axis) regulates exquisitely THs synthesis and secretion 
(Yen, 2001). T4 is the major secreted hormone but acts as a pro-hormone. The 
production of circulating T3, results from the activity of the iodothyronine deiodinase 
enzymes (selenoproteins) D1 and D2 which convert T4 to T3 by 5’monodeiodination 
(Oetting and Yen, 2007). On the contrary, the D3 enzyme inactivates T4 and T3 by 
5’monodeiodination. Therefore, the intracellular level of T3 depends on the relative 
activities of these 3 deiodinases (Bassett et al., 2003). 
The biologically active form of thyroid hormone - triiodothyronine - acts and regulates 
nuclear gene expression through thyroid hormone receptors (TRs), which are members 
of the steroid/thyroid receptor superfamily of nuclear hormone receptors. In the mid-
1980s, two research groups simultaneously published the landmark discovery, which 
showed that TRs were the cellular homologs (c-erbA) of v-erbA, a viral oncogene 
product involved in chick erythoblastosis (Sap et al., 1986; Weinberger et al., 1986). 
Acting as transcription factors, TRs bind to specific DNA sequences known as thyroid 
response elements (TREs), typically located in the upstream promoter regions of T3-
target genes, activating or repressing transcription in response to hormone. In positively 
regulated target genes, TREs generally contain at least two hexameric half-sites 
consisting of the consensus sequence G/AGGTC/GA. In particular, TRs bind to TREs 
in which half-sites are arranged as direct repeats with a four nucleotide spacer (DR4), as 
inverted repeats with a six nucleotide spacer (IP6) or as a palindrome (PAL0) (Aranda 
and Pascual, 2001). Although thyroid hormone receptors are capable of binding DNA at 
TREs as monomers or homodimers, TRs predominantly bind as heterodimers with the 
retinoid X receptor (RXR), another member of the nuclear receptor superfamily. It is 
well established that RXR increases the DNA-binding affinity of TR (Lazar, 2003). 
Numerous analyses of TRs and comparison with other members of the nuclear hormone 
receptor superfamily have yielded thorough information on the structural features of 
TRs. All TRs have a similar domain organisation as that found in all nuclear hormone 
receptors (Fig. 4): an amino-terminal A/B domain; a central DNA-binding domain 
(DBD) or region C containing two zinc finger motifs intercalating with the major and 
minor grooves of TRE nucleotide sequences; a linker region D with a stretch of multiple 
 - 19 - 
lysines necessary for nuclear translocation of the receptor; and a carboxy-terminal 
ligand-binding domain (LBD) (Yen, 2001). 
 
 
 
Fig. 4. A schematic representation of the functional domains of the thyroid hormone 
receptor (Bassett et al., 2003). 
 
More precisely, the N-terminal A/B region, highly variable both in size and sequence 
among various nuclear receptors, contains a transcriptional activation function, referred 
as activation function 1 (AF-1), that can operate autonomously. In contrast to the other 
activation function (AF-2) located in the LBD of liganded nuclear receptors (NRs), AF-
1 can act in a ligand-independent manner when placed outside the receptor. However, in 
the context of its own full-length receptor, AF-1 activity is also controlled by ligand 
binding to the LBD (Germain et al., 2006). The DBD, located in the central portion of 
TR, is the most conserved domain. Within the first of two zinc fingers, each composed 
of four cysteines coordinated with a zinc ion, there is a ‘‘P box’’. This critical region is 
known to be important in sequence-specific recognition of hormone response elements 
by different members of the nuclear hormone superfamily and contacts nucleic acids 
and phosphate groups within the major groove of the TRE. On the other hand, amino 
acids in the second zinc finger form so-called ‘‘D box’’ involved in dimerization 
(Aranda and Pascual, 2001). The D region, considered to serve as a hinge between the 
most highly conserved domains DBD and LBD, allows rotation of the DBD and permits 
the DBD and LBD to adopt different conformations without creating steric hindrance 
troubles (Oetting and Yen, 2007). Thyroid receptor activation occurs when an agonist 
ligand such as TH or similar compounds bind to a hydrophobic pocket in the core of its 
ligand-binding domain, composed of twelve conserved α-helical regions numbered from 
H1 to H12. Upon ligand binding the receptor undergoes a clear conformational change 
in the LBD, particularly in helix 12, which results in changes in TR interaction with co-
activators and co-repressors (Lazar, 1993; Bleicher et al., 2008). 
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Multiple thyroid hormone receptor isoforms and TH analogs 
 
The human TRs are encoded by two genes, α and β, localized in human chromosomes 
17 and 3, respectively. The TRα (NR1A1) and TRβ (NR1A2) genes encode mRNAs 
that are alternatively spliced and generate different mRNA isoforms: TRα1, α2, α3, 
∆α1, ∆α2, β1, β2, β3, ∆β3 (Fig. 5). While it is known that TRα1, α2, β1, β2 proteins are 
expressed in vivo, the expression and physiological relevance of the other isoforms 
remain unclear (Ribeiro, 2008). Moreover, β3/∆β3 locus is present only in rats, but not 
in other vertebrates, including humans (Williams, 2000; Harvey et al., 2007). 
 
 
 
Fig. 5. Properties of major TR isoforms (Bassett et al., 2003). 
 
TR isoforms are widely distributed, although there are differences in concentrations in 
various tissues. For example, TRα is the dominant receptor in the brain, skeletal system 
and mediates most of the synergism between T3 and the sympathetic signalling pathway 
in the heart, whereas TRβ, abundant in liver, is supposed to be the isoform that mediates 
most of T3 effects on lipid metabolism and regulation of metabolic rate. Thus, it made 
sense to develop compounds that selectively act on one of the TRs, allowing for 
selective activation of different T3-mediated pathways (Ribeiro, 2008). Particular 
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interest has been focused on the effects of THs on lipid metabolism and the ability to 
lower cholesterol. However, these results occur whilst inducing a thyrotoxic state, 
including induction of tachycardia and arrhythmia, muscle wasting, suppression of 
thyroid-stimulating hormone (TSH) levels and bone mass loss; all limiting the use of 
THs. Since 1950s, attempts to eliminate these undesired effects were made. A 
promising strategy for treating lipid disorders in euthyroid individuals appeared with a 
new class of halogen-free high-affinity thyroid hormone agonists (Moreno et al., 2008). 
In 1998, the synthesis of 3,5-dimethyl-4(4’-hydroxy-3’-isopropyl benzyl)-phenoxy) 
acetic acid, a TRβ-selective agonist was announced. This novel thyromimetic 
compound, named GC-1, presented some structural changes with respect to the natural 
hormone T3 (Fig. 6): 
• the three iodine residues of T3 were replaced by methyl and isopropyl groups; 
• a methylene linkage replaced the biaryl ether linkage between the two phenol 
groups; 
• the amino acid side-chain at the 1 position changed with an oxyacetic group 
(Chiellini et al., 1998). 
 
OHO
I
I
I
CH2
NH2
COOH
 
CH2HO
CH
H3C
H3C
O
CH2
COOH
CH3
H3C
T3
GC-1
 
 
Fig. 6. Chemical structures of T3 and GC-1. 
 
As a consequence of these modifications GC-1 binds to TRβ1 with approximately the 
same affinity as T3, whereas the novel thyromimetic compound binds to TRα1 with a 
10-fold lower affinity. This TRβ selectivity was seen, not only in binding experiments, 
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but also in dose-response cellular transactivation experiments (Chiellini et al., 1998). 
Recently, the x-ray structures of both thyroid hormone receptor isoforms as bound to 
natural hormone T3 and GC-1, supported by molecular dynamics simulations of the 
complex, permitted the proposal of a β-selectivity mechanism for GC-1. The major 
contributions for isoform-selective binding of GC-1 are the presence of an oxyacetic 
acid ester oxygen, the absence of the amino group relative to T3, the Ser/Asn active-site 
substitution (human (h)TRα has a Ser277 residue, which is substituted by Asn331 in 
hTRβ) and alternate conformations of a conserved Arg residue in the binding pocket 
(Arg228α/Arg282β). While in TRβ a single stable ‘‘productive’’ conformation is 
observed, in which GC-1 interacts effectively with Arg282, whereas this residue 
interacts with the carbonyl group of Asn331, in TRα, ‘‘productive’’ and ‘‘non-
productive’’ conformations can be observed. The selective binding of GC-1 is related to 
the fact that the Ser/Asn active-site substitution increases the space available to a 
conserved Arg residue (Arg228) allowing it to assume multiple conformations. In the 
‘‘productive’’ conformation, identical to that of TRβ, the ligand interacts strongly with 
the Arg228 residue and with the Ser277 by its oxyacetic oxygen. However, TRα 
Arg228 possesses also the ability to flip away from the ligand in ‘‘non-productive’’ 
conformations, which result in loss of a crucial interaction for the stabilization of the 
ligand (Bleicher et al., 2008). 
As reported in the literature, in the first studies in animal models, GC-1 showed 
extremely encouraging results, decreasing total serum cholesterol and triglyceride levels 
in hypercholesterolemic rats without any significant cardiac effects. In particular, it has 
been noticed that GC-1 can retain the beneficial effects of T3 at doses devoid of 
deleterious cardiovascular effects on heart weight, heart rate and mRNAs coding for 
proteins related to cardiac contraction, such as myosin heavy chain α (MHCα), MHCβ 
and sarcoplasmic reticulum calcium adenosine triphosphatase (Serca2) (Trost et al., 
2000). Additional experiments performed in cynomolgus monkeys, having a lipid 
metabolic profile more closely resembling that of a man, showed that the selectivity of 
GC-1 resulting in an improved therapeutic index for lipid lowering relative to cardiac 
effects is also observed in primates (Grover et al., 2004). Successive studies clarified 
the mechanisms involved in the cholesterol-lowering effect of this selective 
thyromimetic compound. Experiments performed in euthyroid chow-fed mice 
demonstrated that GC-1 reduced serum cholesterol and triglyceride levels, increased 
expression of the hepatic high-density lipoprotein (HDL) receptor SR-B1, as well as 
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stimulated bile acid synthesis and excretion, thus regulated important steps in reverse 
cholesterol transport. Moreover, GC-1 at equimolar doses was even more efficient than 
T3 (Johansson et al., 2005). In addition, it has been observed that GC-1 increases the 
metabolic rate, has no effect on food intake and reduces fat mass in female rats after 6 
weeks of treatment, without any apparent loss of skeletal muscle mass (Villicev et al., 
2007). 
Taking into consideration the selective hyperthyroidism of GC-1, this novel compound 
can be considered as a promising prototype for new drugs for the treatment of a variety 
of metabolic disturbances, including high lipid levels or obesity. 
 
Animal models of hepatic steatosis and steatohepatitis 
 
The understanding of the pathogenesis of non-alcoholic liver disease has undoubtedly 
improved with the help of animal models of hepatic steatosis and steatohepatitis which 
have provided the conceptual framework for further investigation. However, the large 
variety of experimental models is confusing and potentially obscures the comparison 
and interpretation of results (Veteläinen et al., 2007). The most frequently used and 
particularly informative models include: genetically obese ob/ob mice, lipoatrophic 
mice and normal rats fed a choline-deficient, methionine-restricted (CMD) diet (Koteish 
and Diehl, 2002). 
A naturally occurring model of non-alcoholic liver disease is represented by ob/ob mice 
which spontaneously develop fatty liver, due to a mutation in the ob gene, which 
encodes leptin, a satiety hormone secreted exclusively by adipocytes. In the absence of 
leptin, a sensor of fat mass, exerting anorectic and thermogenic effects through its 
hypothalamic receptor, ob/ob mice become obese, hyperphagic and inactive. 
Consequently, absence of this adipocyte-derived peptide hormone leads not only to 
NAFLD, but also to dyslipidemia and insulin resistance (Koteish and Diehl, 2002; 
Fishman  et al., 2007). 
On the other hand, transgenic mice with differing degrees of fat loss can be used as 
models for lipoatrophy. An example includes mice that overexpress a truncated version, 
immune to down-regulation, of human sterol regulatory element binding protein-1a 
(SREBP-1a), a key transcriptional regulator for many genes involved in fatty acid and 
cholesterol biosynthesis (e.g. hydroxymethyl-glutaryl-CoA synthase and reductase, fatty 
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acid synthase, stearoyl-CoA desaturase, acetyl-CoA carboxylase, low density 
lipoprotein-receptor) (Shimano et al., 1996; Shimano, 2001; Koteish and Diehl, 2002). 
Other strains of genetically altered mice have a generalized paucity of adipose tissue 
throughout life due to impaired or disordered adipocyte differentiation. This group 
includes: 
1) A-ZIP/F-1 transgenic mice, expressing a dominant-negative protein A-ZIP/F 
(under the control of the adipose-specific aP2 enhancer/promoter), which 
inhibits the DNA binding and function of B-ZIP proteins in both the C/EBP and 
AP-1 families of transcription factors, critical for adipocyte growth and 
differentiation; 
2) transgenic mice with truncated sterol regulatory element binding protein-1c 
(SREBP-1c) in adipose tissue (under the control of the adipocyte-specific aP2 
enhancer/promoter), which is known to be implicated in adipose differentiation. 
Regardless of the mechanism used to reduce the adipose tissue mass, hepatic steatosis, 
leptin-deficiency and severe insulin resistance are observed in all models with 
generalized lipoatrophy (Moitra et al., 1998; Shimomura et al., 1998). 
Nonetheless, a particularly useful model, which emphasizes the importance of oxidative 
stress in the pathogenesis of hepatic steatosis and steatohepatitis, is represented by 
studies of animals fed the CMD diet (Lombardi et al., 1968; Koteish and Diehl, 2002). 
 
Choline homeostasis 
 
The study of the characteristics and metabolites of choline is of meaningful importance 
to understand the mechanism of hepatic steatosis induced by the CMD diet. Choline, a 
positively charged quaternary amine (trimethyl-β-hydroxy-ethylammonium), was first 
isolated from ox bile (the Greek word for bile is chole) by Strecker in 1862. In late 
1930s, Best and Huntsman discovered that choline deficiency results in fatty liver (Li 
and Vance, 2008). In 1998, choline was identified as an essential nutrient for humans by 
the National Academy of Sciences. This dietary component, required for normal 
function of all cells, influences stem cell proliferation and apoptosis, as well as neural 
tube development. Disturbed choline transport has been proposed as an important factor 
in neurodegenerative (e.g. Alzheimer’s disease) and immunological disorders (Michel et 
al., 2006). Utilized for the synthesis of essential lipid components of the cell 
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membranes - phosphatidylcholine (PC) and sphingomyelin, choline assures the 
structural integrity and signalling functions (Li and Vance, 2008). The Kennedy 
pathway (Fig. 7) for de novo synthesis of PC, essential for the formation of membrane 
phosphatidylcholine in all nucleated cells, results from the phosphorylation of the 
majority of cellular choline by choline kinase (CK) in the cytoplasm of the cell to 
phosphocholine, to which cytidine triphosphate (CTP) is added by CTP:phosphocholine 
cytidyltransferase (Pcyt1) to form cytidine diphosphate (CDP)-choline. The ultimate 
step necessary for the formation of this predominant phospholipid (>50%) in most 
mammalian membranes, involves the reaction of CDP-choline with diacylglycerol 
(DAG) in the endoplasmic reticulum, catalyzed by the membrane-bound enzyme, CDP-
choline:DAG cholinephosphotransferase (CPT) (Michel et al., 2006). 
 
 
 
Fig. 7. Choline metabolic pathways (Michel et al., 2006). 
 
ADP, adenosine diphosphate; ATP, adenosine triphosphate; BHMT, betaine:homocysteine 
methyltransferase; B12, vitamin B12; CDP, cytidine diphosphate; CK, choline kinase; CPT, CDP-
choline:DAG cholinephosphotransferase; CMP, cytidine monophosphate; CTP, cytidine triphosphate; 
DAG, diacylglycerol; MAT, methionine adenosyltransferase; methylTHF, 5-methyltetrahydrofolate; 
MS, methionine synthase; MTHF, 5,10-methylene-tetrahydrofolate; PAF, platelet-activating factor; 
PCP, phosphatidylcholine:ceramidecholine phosphotransferase; Pcyt1, CTP:phosphocholine 
cytidyltransferase; PEMT, phosphatidylethanolamine N-methyltransferase; PLA, phospholipase A2; PPi, 
pyrophosphate; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate. 
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Moreover, choline is known to be a major source of methyl groups. Betaine, one of 
choline’s metabolites, participates in the methylation of homocysteine to form 
methionine, whose derivative S-adenosylmethionine (SAM) serves as an active methyl 
donor for many enzymatic methylations. Despite the fact that only a small fraction of 
dietary choline is acetylated, it plays a key role in neurons as the precursor of the 
neurotransmitter acetylcholine (Zeisel, 2000; Zeisel, 2006). It is important to underline 
that choline is not only derived from diet. During evolution, the liver has retained a 
backup pathway for choline moiety production from the second most abundant 
phospholipid membrane component, phosphatidylethanolamine (PE). PE is transformed 
to phosphatidylcholine in a three-step methylation by SAM, which is catalyzed by 
phosphatidylethanolamine N-methyltransferase (PEMT). Then, choline can be 
generated from PC via the action of phospholipases. It has been shown that mice that 
lack PEMT (PEMT
-/-
), when fed the CMD diet to restrict the availability of choline, 
rapidly develop hepatic steatosis, severe liver damage and die from liver failure after 3 
days (Li and Vance, 2008). Moreover, extensive studies on the role of the PEMT 
pathway in animal models support the hypothesis, that female rats are less susceptible to 
choline deficiency than the males. The difference is believed to be attributable to 
estrogen status, enhancing females’ capacity to produce phosphatidylcholine via the 
PEMT pathway (Kirsch et al., 2003; Michel et al., 2006). 
 
Mechanism of steatosis development and key molecular events while 
feeding the choline-deficient, methionine-restricted (CMD) diet 
 
The functional consequence of the CMD diet is a rapid accumulation of lipids in hepatic 
cytosol. This phenomenon is known since the discovery of choline as a lipotrope in 
1932 and triglycerides represent the main component of accumulated fatty droplets. The 
proposed biochemical basis of such a significant impact on liver function and lipid 
metabolism is attributable to impaired transport of TGs outside the hepatocytes. 
Reduced efficiency of VLDL-TG production occurs because choline is predominantly 
utilized as precursor of PC, the principal phospholipid comprising the outer coat of 
VLDL-TG particles (Yao and Vance, 1988; Zeisel, 1990). 
Feeding the choline-deficient, methionine-restricted diet is a frequently employed 
nutritional model, resulting in liver injury presenting close pathological and biochemical 
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similarities to human NASH (Romestaing et al., 2007; Veteläinen et al., 2007; Rinella 
et al., 2008). In addition to the accumulation of triglycerides occurring within 24 hours 
of choline restriction, numerous biochemical and molecular biology studies on the 
effects of the CMD diet have been performed. There is compelling evidence that one of 
the factors which determine how rapidly a diet deficient in choline and restricted in 
methionine will induce pathology is the demand for choline as methyl donor. Betaine, 
folate and S-adenosylmethionine concentrations are markedly diminished in livers of 
rats fed the choline-deficient, methionine-restricted diet (Zeisel, 1990). Concomitantly, 
it has been revealed that an early event in choline deficiency is the appearance of 
oxidized lipids, DNA and proteins, suggesting impaired oxidative balance, as well as 
immediate evidence of lipid peroxidation of the nuclear and mitochondrial membranes. 
The formation of conjugated dienes has been reported (Rushmore et al., 1984) as a 
consequence of this free radical-mediated mechanism leading to oxidative destruction 
of polyunsaturated fatty acids constitutive of cellular membranes (Seki et al., 2002). 
Oxidative damage to DNA, particularly the formation of 8-hydroxydeoxyguanosine (8-
OH-dG) lesions, generally accepted as one of the most reliable markers of oxy radical-
induced DNA damage (Cooke et al., 2003), occurs within the time frame of lipid 
peroxidation (Rushmore et al., 1986; Yoshiji et al., 1992). Furthermore, knowing that 
mitochondrial β-oxidation is the dominant oxidative pathway for the removal of fatty 
acids under normal physiologic conditions, but also a major source of reactive oxygen 
species (ROS), it has been demonstrated that mitochondrial respiration, in regard to 
complex I-linked (NADH-dependent) respiration, is altered in association with 
significantly increased hydrogen peroxide (H2O2) leakage during choline withdrawal 
(Hensley et al., 2000). Consequently, alterations of specific mitochondrial functions, 
impaired mitochondrial respiratory chain activity lead to an increased production of 
ROS and an impaired synthesis of ATP, critical for maintaining cellular integrity 
(Vendemiale et al., 2001). Compared with normal liver, under fed conditions, fatty 
livers show also low concentration of glutathione, the main natural antioxidant essential 
for liver function and integrity, responsible for free radical species detoxification. This 
can be explained by the fact that methionine is required for the transsulfuration pathway 
of glutathione precursor synthesis.(Lu et al., 2001; Vendemiale et al., 2001). All these 
events are considered to have the potential to induce directly both inflammation and 
liver fibrosis (Browning and Horton, 2004). 
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Marked species-related differences in the effects of feeding the CMD have been 
identified. It has been demonstrated that rats display a greater propensity to develop 
fatty change, while inflammation and necrosis are minor features. Mice, in contrast, 
have less steatosis and lower hepatic triglyceride levels, but show a marked increase in 
inflammatory foci (Kirsch et al., 2003; Kashireddy and Rao, 2004b). 
Furthermore, it has been observed that choline deficiency alone is sufficient to trigger 
carcinogenesis, develop preneoplastic hepatocyte nodules and hepatocellular carcinoma, 
in the absence of any known carcinogen (Ghoshal and Farber, 1984; Ghoshal et al., 
1987; Chandar and Lombardi, 1988). It is noteworthy that the CMD diet-fed rats not 
only have a higher incidence of spontaneous hepatocarcinoma, but are also markedly 
sensitized to the effects of administered carcinogens (Zeisel, 1990). From the results of 
numerous experiments, it has been confirmed that feeding the choline-deficient, low in 
methionine diet strongly enhances tumour development in rats pretreated with a single 
initiating dose of diethylnitrosamine (DENA) (Yokoyama et al., 1985; Sawada et al., 
1990). CMD diet effectively promotes the evolution of initiated cells to foci of altered 
γ-glutamyltranspeptidase (GGT)-positive hepatocytes. The expression of this enzyme, a 
common biochemical marker for early preneoplastic lesions, is highest in embryo livers, 
decreases rapidly to the lowest levels after birth and is re-expressed during the 
development of HCC (Shinozuka et al., 1979). 
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AIM OF STUDY 
______________________________________________________________________ 
 
Non-alcoholic fatty liver disease (NAFLD) that may develop fibrosing steatohepatitis or 
progress to cirrhosis, end-stage liver disease and hepatocellular carcinoma is a highly 
prevalent disease. Ineffectiveness of current drug therapies and an increasing need for 
new therapeutic tools for the treatment of NAFLD led us to investigate the effect of the 
thyroid hormone triiodothyronine (T3) on fatty liver and steatohepatitis. For this study, 
we employed a choline-deficient, methionine-restricted (CMD) dietary model in rats. In 
particular, we wanted to examine if: 
1a. concurrent administration of the CMD diet and T3 results in the prevention 
of fatty liver; 
1b. feeding the CMD diet followed by feeding the CMD diet containing T3 
reverses CMD-induced fatty liver. 
 
Subsequently, aware of the concomitant induction of a thyrotoxic state during T3-based 
therapies, we focused our attention on GC-1, an agonist of the thyroid hormone receptor 
β isoform, which has no significant side effects on heart rate. Strongly convinced that 
selective thyromimetics may offer several types of therapeutic potential and are 
interesting candidates for further exploration, we investigated if: 
2a. co-administration of GC-1 with the CMD diet prevents CMD-induced fat 
accumulation; 
2b. CMD dietary feeding followed by feeding the CMD diet containing GC-1 
reverses fully established fatty liver. 
 
Since the measurement and interpretation of the endogenous metabolite profile from a 
biological sample has been recognised as a valuable tool in life sciences, we were 
encouraged to: 
3. extend the understanding of the mechanisms accompanying lipid 
accumulation and decrease in the liver during treatment with GC-1, applying a 
metabolomic technique. This data was made available thanks to our 
collaboration with the University of Cambridge. 
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MATERIALS AND METHODS 
______________________________________________________________________ 
 
Animals and diets 
 
Male Fischer (F-344) rats, 6-8 weeks of age, body weight ranging from 100-125 g, 
purchased from Charles River (Milan, Italy) were used for the experiments. On arrival, 
the animals were maintained on a rodent standard diet (Standard Diet 4RF21, 
Mucedola, Settimo Milanese, Italy), given food and water ad libitum with alternating 
12-hour dark/light cycles and acclimatized to laboratory conditions for a minimum of 
seven days before the start of the experiment. Temperature and humidity were 
controlled for the entire period of experimentation. All procedures were performed in 
accordance with the Universities Federation for Animal Welfare Handbook on the Care 
and Management of Laboratory Animals and the guidelines of the animal ethics 
committee of the University of Cagliari. After acclimatization, the rats were randomized 
into various experimental groups and fed as follows: 
 
1) CMD diet (Mucedola, Settimo Milanese, Italy), prepared according to the original 
formula (Shinozuka et al., 1978), containing a limited (0,2%) amount of methionine, in 
view of the efficient endogenous synthesis of choline from methionine; 
 
2) CMD diet supplemented with T3 at a final concentration of 4 mg/kg of diet 
(Mucedola, Settimo Milanese, Italy); 
 
3) CMD diet supplemented with GC-1 (synthesized as described by Chiellini et al. in 
1998) at a final concentration of 5 mg/kg of diet (Mucedola, Settimo Milanese, Italy); 
 
4) choline-supplemented (CS) diet (Mucedola, Settimo Milanese, Italy), identical to the 
CMD diet except that it was supplemented with choline bitartrate (1 g/kg). 
 
For detailed components of the Standard Diet 4RF21, CS and CMD diets see Table 1. 
While eating the experimental formulas, all animals had free access to water. 
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 STANDARD DIET 
4RF21 
CS DIET 
 
CMD DIET 
 
 
 
 
Ingredients 
 
 
 
 
 
Wheat; Maize; 
Soybean, dehulled 
extracted toasted; Corn 
gluten feed; Wheat 
straw; Fish meal; 
Lucerne meal; Mineral 
dicalcium phosphate; 
Calcium carbonate; 
Sodium chloride; Whey 
powder; Soybean oil; 
D,L-Methionine; Yeast 
 
 
Sucrose; Coconut oil; 
Starch; Dextrine; 
Extracted peanut meal; 
Soy protein; Corn oil; 
Cellulose; Dicalcium 
phosphate; Potassium 
citrate; Magnesium 
oxide; Sodium chloride; 
L-Cystine 
 
Sucrose; Coconut oil; 
Starch; Dextrine; 
Extracted peanut meal; 
Soy protein; Corn oil; 
Cellulose; Dicalcium 
phosphate; Potassium 
citrate; Magnesium 
oxide; Sodium chloride; 
L-Cystine 
 
 
 
Vitamins 
 
 
 
 
Vitamin A 
Vitamin D3 
Vitamin E 
Vitamin B1, B2, B6, B12 
Vitamin K3 
Niacin 
Folic acid 
d-Pantothenic Acid 
Biotin 
Choline 1000 mg 
 
 
Vitamin A 
Vitamin D3 
Vitamin E 
Choline 1000 mg 
 
 
Vitamin A 
Vitamin D3 
Vitamin E 
 
 
 
 
Minerals 
 
 
 
 
 
Fe (ferrous sulphate 
heptahydrate) 
Mn (manganous 
sulphate monohydrate) 
Zn (zinc sulphate 
monohydrate) 
Cu (copper sulphate 
pentahydrate) 
J (calcium iodate 
anhydrous) 
Co (basic cobaltous 
carbonate monohydrate) 
 
 
Cu (copper sulphate 
pentahydrate) 
Se (sodium selenite) 
 
Cu (copper sulphate 
pentahydrate) 
Se (sodium selenite) 
 
 
Analysis % 
 
Protein: 18.5 
Fat: 3.0 
Fibre: 6.0 
Ash: 7.0 
 
 
Protein: 12.0 
Fat: 16.0 
Fibre: 2.0 
Ash: 3.5 
 
 
Protein: 12.0 
Fat: 16.0 
Fibre: 2.0 
Ash: 3.5 
 
 
Table 1. Components of the Standard Diet 4RF21, CS and CMD diets. 
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Experimental protocols 
 
In experimental protocol I (Fig. 8), rats were fed the CS or the CMD diet for 1, 3, 5 
and 7 days and sacrificed on the first, third, fifth and seventh day. 
In experimental protocol II (Fig. 9), rats were fed the CS, CMD diet or the CMD diet 
supplemented with T3 for 1 week and sacrificed on the seventh day. 
For experimental protocol III (Fig. 10), rats were fed the CMD diet for 10 weeks and 
then divided into two groups. The first group was maintained on the CMD diet for an 
extra week, while the second group was fed the CMD+T3 diet. Rats on the choline-
supplemented (CS) diet for 11 weeks were used as the control group. Animals were 
sacrificed at the end of the eleventh week. 
In experimental protocol IV (Fig. 11), rats were fed the CS, CMD diet or the CMD 
diet supplemented with GC-1 for 2 weeks and sacrificed on the fourteenth day. 
For experimental protocol V (Fig. 12), rats were fed the CMD diet for 10 weeks and 
then divided into two groups. The first group was maintained on the CMD diet for 
another two weeks, while the second group was fed the CMD+GC-1 diet. Rats on the 
choline-supplemented (CS) diet for 12 weeks were used as the control group. Animals 
were sacrificed at the end of the twelfth week. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Schematic representation of the design of the experimental protocol I. 
5 to 6 male Fischer rats (F-344) per group were used. 
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Fig. 9. Schematic representation of the design of the experimental protocol II. 
5 to 6 male Fischer rats (F-344) per group were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Schematic representation of the design of the experimental protocol III. 
5 to 6 male Fischer rats (F-344) per group were used. 
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Fig. 11. Schematic representation of the design of the experimental protocol IV. 
5 to 6 male Fischer rats (F-344) per group were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Schematic representation of the design of the experimental protocol V. 
 5 to 6 male Fischer rats (F-344) per group were used. 
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Histology 
 
Immediately after the animals were killed, sections of the liver were fixed in 10% 
buffered formalin and paraffin-embedded for staining with hematoxylin-eosin for 
routine morphology and the evaluation of hepatic steatosis. The remaining liver was 
snap-frozen in liquid nitrogen and kept at -80 °C until use. 
 
 
Lipid peroxidation assay (LPO assay) 
 
Approximately 100 mg of liver tissue was homogenized with an Ultra Turrax T8 stirrer 
(IKA Labortechnik, Staufen, Germany) in ice-cold 20 mM Tris-HCl buffer (pH 7.4) to 
produce a 1/10 homogenate. The crude homogenate was centrifuged at 7000 rpm for 15 
minutes at 4°C. Aliquots of the supernatant were used either for protein determination 
or to calculate lipid peroxidation. 
Lipid peroxidation was assessed by measuring the concentration of malondialdehyde 
(MDA) and 4-hydroxyalkenals (4-HDA) using the Bioxytech® LPO-586 kit
TM
 (Oxis 
International, Portland, OR, USA). This kit takes advantage of a chromogenic reagent 
(N-methyl-2-phenylindole, R1) which reacts with MDA and 4-HDA at 45°C yielding a 
stable chromophore with maximal absorption at a wavelength of 586 nm. The assay was 
conducted according to the manufacturer’s instructions to minimise undesirable 
artifacts. 
 
 
Determination of hepatic TGs 
 
Lipid extraction and measurement of TGs was performed according to Schroeder-
Gloeckler et al. (2007). Liver samples were homogenized in 0.5M NaCl, and a 200 µl 
aliquot of the homogenate was mixed with 500 µl of methanol and 250 µl of 
chloroform. Following centrifugation, the lower, organic phase was collected. Complete 
extraction of any residual lipids was achieved by re-extracting with 250 µl 
chloroform:methanol (9:1). The organic phase was separated by centrifugation and 
combined with the first extraction. Samples were dried under flowing nitrogen. The 
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lipids were dissolved in a solution of 90% isopropanol:10% Triton X-100 (2%) to 
disperse the TGs for assay. 
Taking into consideration that triglycerides, esters of fatty acids and glycerol, do not 
circulate freely in plasma, the most common methods for triglycerides determination 
involve their enzymatic or alkaline hydrolysis to glycerol and free fatty acids, followed 
by either colorimetric or fluorometric measurement of the glycerol released. In our 
study, TGs were measured colorimetrically using a commercially available kit from 
Sigma-Aldrich (Serum Triglyceride Determination Kit-TR0100, Sigma-Aldrich, Milan, 
Italy). We followed the procedure of enzymatic hydrolysis by lipase. 
 
Triglyceride Assay Enzymatic Reactions: 
 
 
 
ESPA: sodium N-ethyl-N-(3-sulfopropyl)m-anisidine 
A quinoneimine dye shows an absorbance maximum at 540 nm. 
 
 
Biochemical analysis: serum TGs, alanine aminotransferases (ALTs) 
and aspartate aminotransferases (ASTs) 
 
Immediately after sacrifice, blood samples were collected from the inferior vena cava, 
centrifuged at 1500 rpm for 20 minutes and serum was analyzed for TGs, ASTs, and 
ALTs, using a commercially available kit from Sigma Diagnostics (Sigma-Aldrich). 
 
 
 
triglycerides 
lipoprotein lipase 
glycerol + fatty acids 
glycerol + ATP 
glycerol kinase 
glycerol-1-phosphate + ADP 
glycerol-1-phosphate + O2 
glycerol phosphate 
oxidase 
dihydroxyacetone phosphate + H2O2 
H2O2 + 4-aminoantipyrine + ESPA quinoneimine dye + H2O 
peroxidase 
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Northern blot analysis 
 
Total RNA was extracted from rat liver by homogenization with TRIzol isolation 
reagent (Invitrogen, San Giuliano, Milan, Italy). 30 µg of total RNA was loaded on a 
1% formaldehyde/agarose gel containing ethidium bromide for RNA detection at a UV 
lamp and blotted on Hybond-XL membrane (Amersham Biosciences, Little Chalfont, 
Buckinghamshire, UK). RNA concentration was determined spectrophotometrically at 
260 nm. Probe for 18S was prepared from total RNA using SuperScript TM III One-
Step RT-PCR System with Platinum TaqDNA Polymerase (Invitrogen). Polymerase 
chain reaction (PCR) primers for 18S were as follows: forward, 
CATTCGAACGTCTGCCCTAT; reverse, CCCTCTTAATCATGGCCTCA. Probes for 
peroxisomal acyl-CoA oxidase (ACO), mitochondrial carnitine-palmitoyltransferase1A 
(CPT1A), mitochondrial trifunctional enzyme-alpha subunit (MTPα), and mitochondrial 
trifunctional enzyme-beta subunit (MTPβ) were prepared from total RNA, reverse-
transcribed with Thermo-Script RTPCR System (Invitrogen Carlsbad, CA, USA) and 
PCR amplified with Platinum TaqDNA Polymerase (Invitrogen) using primers detailed 
in Table 2. DNA probes were labeled with [α-32P]dCTP by random priming (Ready to 
go DNA labeling beads; Amersham Biosciences). Unincorporated nucleotides were 
removed with Microspin G50 columns (GE Healthcare, Slough, Berkshire, UK). 
Membranes were exposed to autoradiographic film (Eastman Kodak, Rochester, NY, 
USA; Sigma Chemical, St. Louis, MO, USA). 
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PRIMER SEQUENCES 
 
 
ACO 
peroxisomal acyl-CoA 
oxidase 
 
FORWARD TTGGGATCCCACTGCTGTGAGAATA 
REVERSE AACTATATTTGGCCAATTTTGTGGAACC 
 
 
CPT1A 
mitochondrial 
carnitine-
palmitoyltransferase1A 
 
FORWARD CAAGGACATGGGCAAGTTTT 
REVERSE GGCACTGTTCTCAGCATTGA 
 
 
MTP-α 
mitochondrial 
trifunctional enzyme-
alpha subunit 
 
FORWARD TGACGCTGTGAAGACTGGAC 
REVERSE TGTTGCTGGCGAAGATACAG 
 
 
MTP-β 
mitochondrial 
trifunctional enzyme-
beta subunit 
 
FORWARD CAGCTGTCCAGACCAAGTCA 
REVERSE TCCTTCATCCTGTGCCTTCT 
 
 
18S 
 
FORWARD CATTCGAACGTCTGCCCTAT 
REVERSE CCCTCTTAATCATGGCCTCA 
 
 
Table 2. Primer sequences. 
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Western blot analysis 
 
Total cell extracts were prepared from frozen livers powdered in liquid nitrogen cold 
mortar. Equal amounts of powder (~50 mg) from three different animals were pooled 
per each sample point and re-suspended in 1 ml Triton lysis buffer (1% Triton X-100, 
50 mM Tris-HCl pH 7.4, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 
mM PMSF, 5 mM iodoacetic acid, 10 mg/ml each of aprotinin, pepstatin, leupeptin). 
Several protease inhibitors were added to the isolation buffer to minimize protein 
degradation during the isolation protocol. After vortexing, extracts were incubated 30 
minutes on ice, centrifuged at 12000 rpm at 4°C, and the supernatants were recovered. 
All inhibitors used were purchased from Boehringer Mannheim (Mannheim, Germany) 
with the following exception: PMSF, NaF, and DTT, which were purchased from Sigma 
Chemical (St. Louis, MO, USA), and iodoacetic acid, which was from ICN Biomedicals 
(Irvine, CA, USA). The protein concentration of the resulting total extracts was 
determined according to the method of Bradford (1976) using bovine serum albumin as 
standard (DC Protein Assay, Bio-Rad Laboratories, Hercules, CA, USA). 
For immunoblot analysis, equal amounts (from 100 to 150 µg/lane) of proteins were 
electrophoresed on SDS 12% or 8% polyacrylamide gels (Sigma Chemical, St. Louis, 
MO, USA). Acrylamide and bis-acrylamide were purchased from ICN Biomedicals 
(Irvine, CA, USA). After gel electrotransfer onto nitrocellulose membranes (Osmonics, 
Westborough, MA, USA) to ensure equivalent protein loading and transfer in all lanes, 
the membranes and the gels were stained with 0.5% (w/v) Ponceau S red (ICN 
Biomedicals, Irvine, CA, USA) in 1% acetic acid and with Coomassie blue (ICN 
Biomedicals, Irvine, CA, USA) in 10% acetic acid, respectively. After blocking with 
5% non-fat dry milk or 5% BSA in Tris-buffered saline/Tween 20 (Sigma Chemical, St. 
Louis, MO, USA) at room temperature for 1 hour or overnight at 4°C, membranes were 
washed in TBS-T and then incubated with the appropriate primary antibodies diluted in 
blocking buffer. Whenever possible the same membrane was used for detection of the 
expression of different proteins. Depending on the origin of primary antibody, filters 
were incubated with anti-mouse, anti-rabbit or anti-goat horseradish peroxidise-
conjugated immunoglobulin G (IgG; Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Immunoreactive bands were identified with a chemiluminescence detection system, as 
described by the manufacturer (Supersignal Substrate; Pierce, Rockford, IL, USA). 
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The intensity of the bands was quantified using Scion Image (NIH, Scion Corporation, 
Bethesda, USA) 
 
 
Antibodies 
 
Following primary antibodies were used: 
 
 mouse monoclonal antibodies against actin (clone AC40; Sigma Chemical); 
 
 rabbit polyclonal antibodies against L-FABP (Abcam, Cambridge, UK), signal 
transducer activator of transcription 3 (STAT 3), phospho-STAT 3 (Tyr705), 
stress-activated protein kinase (SAPK)/Jun N-terminal kinase (JNK), phospho-
SAPK/JNK (Cell Signaling Technology, Beverly, MA, USA); 
 
 goat polyclonal antibodies directed against cyclooxygenase-2 (COX)-2 (M-19) 
(Santa Cruz Biotechnology). 
 
 
Statistical analysis 
 
Instant software (Instat; GraphPad, San Diego, CA, USA) was used to analyze the data. 
One-way analysis of variance (ANOVA) with post hoc analysis using Tukey’s multiple 
comparison test was used for parametric data. The results of multiple observations are 
presented as the means ± SE of at least 2 separate experiments. A value of P<0.05 was 
regarded as a significant difference between groups. 
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Ultra-performance liquid chromatography-quadrupole time-of-flight-
mass spectrometry (UPLC-QTOF-MS) 
 
Sample Preparation 
 
Liver tissue was harvested from male Fischer (F-344) rats on CMD, CMD+GC-1, CS, 
and rodent standard (Standard Diet 4RF21) diets. Tissue was examined for the CMD, 
CMD+GC-1 groups after 3, 7, 14 days (n=5 for each) and for the CS (n=3 for each) and 
standard diet groups (n=5 for each). In order to separate lipids from water soluble 
metabolites, frozen liver (100 mg wet weight) was ground in liquid nitrogen and tissue 
samples were subjected to methanol and chloroform extraction in a 2:1 ratio. Then, lipid 
samples were re-dissolved in a 1:1 water:choloroform mixture for mass spectral 
analysis. 
 
UPLC-QTOF-MS 
 
The total lipid extracts were analyzed on a Waters (Milford, MA, USA) Q-TOF Ultima 
mass spectrometer coupled to an Acquity UPLC system. Samples were maintained in 
the autosampler prior to injection. A Bridged Ethylene Hybrid (BEH) C8 2.1 x 100 mm 
column (Waters; Milford, MA, USA) with 1.7 µm particle size was used at 65 ºC. 
Solvent A (water, 10 mM NH4Ac, 0.01% HCOOH) and solvent B (LC/MS grade 
acetonitrile/isopropanol 5:2, 10 mM NH4Ac, 0.01% HCOOH) were run from 60% B to 
100% B in 8 minutes and held at 100% for 2 minutes before re-equilibrating the column 
at the starting conditions. The flow rate was 600 µl/min and the eluent was split two 
ways with one part going to waste and the other to the mass spectrometer. The resulting 
injection time was 12.5 minutes. The Ultima mass spectrometer (Waters; Milford, MA, 
USA) was operated in positive electrospray ionisation (ESI) mode. Data was collected 
between 80 and 1500 Da, with a scan time of 0.5 seconds. The source temperature was 
set at 100ºC and nitrogen was used as desolvation gas (~800L/h) at 300ºC. The voltages 
of the sampling cone and capillary were 35V and 3.2kV, respectively. Samples were 
analyzed in a randomized order with injection volumes of 2, 4, 6 and 8 µL. A blank 
followed by a pooled quality control sample was run between every 10 analyses to 
ensure instrumental stability was maintained through the course of data acquisition. 
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Statistical analysis 
 
Data from UPLC-QTOF-MS analysis were pre-processed and aligned by using XCMS 
(various forms (X) of chromatography mass spectrometry) according to the literature 
(Smith et al., 2006). Retention corrected peak groups were then used as input into 
SIMCA-P version 11.5 (Umetrics, Umea, Sweden). Principal component analysis 
(PCA) models were initially built to look for outliers, and subsequently supervised 
partial least squares-discriminant analysis (PLS-DA) modelling was performed. 
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RESULTS AND DISCUSSION 
______________________________________________________________________ 
AIM 1a 
Effect of T3 on the prevention of CMD-induced fatty liver 
 
 
The starting point for examining the potential effect of T3 on the prevention of fatty 
liver was the establishment of the dynamics of fat accumulation in rats fed the CMD 
diet. For this purpose, we designed and followed the experimental protocol I. The 
macroscopic appearance of the livers from the animals fed the CMD diet for 3, 5 and 7 
days resulted enlarged, pale or yellow blotchy on the surface, suggesting deposits of 
hepatic fat compared to the livers of the animals fed the CS for the same time period. 
These characteristics were not evident after 1-day-feeding with the CMD or CS diet. 
After calculating the liver-to-body weight ratio in animals fed the CMD or CS diet for 
1, 3, 5 or 7 days, we observed that after only 3 days this parameter was significantly 
higher in the CMD diet-fed rats when compared to the CS diet-fed animals (P<0.005) 
(Fig. 13). This difference was further increased after 5 and 7 days of feeding the CMD 
or CS diet (P<0.001) (Fig. 13). Successively, hematoxylin-eosin stained liver sections 
were used to confirm gradual fat accumulation and evaluation on a semi-quantitative 
basis was performed. The system devised for this study scored steatosis according to the 
percentage of hepatocytes showing lipid accumulation as follows: 0: 0%; 1: 0% to 33%; 
2: 33% to 66%; 3: 66% to 100% (a grading system proposed by Brunt et al., 1999). We 
remarked that after 7 days of the CMD diet feeding, the highest level of the severity of 
hepatic steatosis (grade 3) was reached (Fig. 14). Interestingly, we also noted a 
difference in the distribution of fat accumulation. Hepatic steatosis resulted more severe 
in the left lateral lobe than in the middle lobe (terminology of liver anatomy according 
to Higgins and Anderson, 1931). 
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Fig. 13. Liver-to-body weight ratio of rats fed the CS or CMD diet for 1, 3, 5 and 7 
days. Data is presented as mean ± SE; 5 rats per group. 
**
P<0.005 vs. CS 3d, 
°°°P<0.001 vs. CS 5d, 
###
P<0.001 vs. CS 7d. 
 
 
 
 
Fig. 14. Histological pattern (hematoxylin-eosin stained) of liver sections from rats fed 
the CMD diet for 1, 3, 5, 7 days (original magnification x10). 
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In order to examine the therapeutic potential of T3 in the treatment of CMD-induced 
steatosis, we studied the effect of concurrent administration of the CMD diet and T3 on 
the prevention of fatty liver. To test this hypothesis we used the experimental protocol 
II. We observed that in all experimental groups, physical activity and behaviour were 
similar. Appearance of animals remained healthy. No significant change in body weight 
occurred in rats fed the CMD diet for 1 week when compared to the CS diet-fed animals 
(Table 3). However, depriving rats of choline and methionine for seven days caused an 
~25% increase of liver weight. The liver-to-body weight ratio was higher in the CMD 
diet-fed rats compared to the CS diet-fed and CMD+T3 diet-fed animals (P<0.001) 
(Table 3). While the CMD+T3 diet-fed rats had a serum triglyceride level similar to that 
of CMD-diet rats (Table 4), the mean body weight, liver weight and liver-to-body 
weight ratio were significantly less than that of the CMD diet-fed rats (Table 3). 
It is well known that serum biochemical parameters provide helpful information in 
assessing liver damage. Alterations of the hepatocellular membrane integrity due to 
hepatocyte injury or metabolic disturbances (hepatic glycogen and lipid accumulation) 
result in a release of soluble cytosolic enzymes (out of the cytoplasm) into peripheral 
blood causing their increase when measured. Currently, alanine aminotransferase (ALT, 
formerly SGPT; found in the cytosol) and aspartate aminotransferase (AST, formerly 
SGOT; found in both the cytosol and mitochondria) are widely employed examples of 
such hepatic “leakage” enzymes. Moderate to marked increase in serum ALT and AST 
is observed during hepatocellular injury. However, having both cytosolic and 
mitochondrial isoforms, AST requires relatively severe forms of liver necrosis for its 
increase to occur compared to ALT. Nonetheless, ALT is recognised as more specific 
for the hepatocytes because of its high activity in the hepatocellular cytoplasm 
(Ramaiah, 2007). 
As far as biochemical parameters are concerned, serum ALT and AST were increased in 
the CMD diet-fed animals compared to the CS diet-fed rats, whereas feeding the 
CMD+T3 diet caused a decrease in the levels of serum ALT and AST compared to the 
CMD diet-fed rats (Table 4). 
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Treatment 
 
Body Weight (g) 
 
Liver Weight (g) Liver-to-Body 
Weight Ratio (%) 
 
CS 
 
 
144.2 ± 2.0 
 
 
6.42 ± 0.19 
 
 
4.51 ± 0.03 
 
 
CMD 
 
 
147 ± 2.5 
 
 
8.09 ± 0.15 
***
 
 
 
5.53 ± 0.06 
***
 
 
 
CMD+T3 
 
 
115.0 ± 2.4 
###
 
 
 
5.81 ± 0.35 
###
 
 
 
4.72 ± 0.14 
###
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.005, 
###
P<0.001 vs. CMD 
 
Table 3. Effect of T3 on body weight, liver weight, liver-to-body weight ratio in rats fed 
the CMD diet for 1 week. Values are expressed as means ± standard error (SE) of 5 to 6 
animals per group. 
 
 
Treatment 
 
TG (mg/dl) AST (U/L) ALT (U/L) 
 
CS 
 
 
186.8 ± 11.9 
 
 
124.5 ± 5.1 
 
 
32 ± 1.9 
 
 
CMD 
 
 
136.4 ± 18.2 
*
 
 
 
149 ± 2.1 
**
 
 
 
57 ± 4.6 
** 
 
 
CMD+T3 
 
 
122.2 ± 15.8 
*
 
 
 
125.2 ± 7.2 
#
 
 
 
42 ± 2.8 
#
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.005, 
###
P<0.001 vs. CMD 
 
Table 4. Effect of T3 on serum levels of TGs, ALTs, and ASTs in rats fed the CMD diet 
for 1 week. Values are expressed as means ± standard error (SE) of 5 to 6 animals per 
group. 
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Histological examination was the successive step. As evident from Figure 15, livers of 
the CMD diet-fed rats showed severe macrovesicular steatosis with the presence of 
abundant fat droplets involving all hepatic lobules, whereas no pathological changes 
were seen in the CS diet-fed animals. The rapid accumulation of hepatic TGs confirmed 
by biochemical determination, is recapitulated in Figure 16. Histological examination 
(Fig. 15) and biochemical determination of hepatic TG content (Fig. 16) showed an 
almost complete absence of lipid accumulation in the CMD+T3 diet-fed rats. It 
demonstrates that T3 completely prevents the induction of hepatic steatosis by the CMD 
diet. Moreover, as previously mentioned, prevention of steatosis by T3 is accompanied 
by a decrease in the levels of serum ALT and AST compared to the CMD diet-fed rats 
(Table 4). 
 
 
Fig. 15. Representative histology of liver tissue. Hematoxylin-eosin stained liver 
sections from rats fed the CS, CMD and CMD+T3 diet for 1 week (original 
magnification x20). 
 
Fig. 16. Hepatic triglyceride content. Values are expressed as means ± SE; 5 rats per 
group. 
***
P<0.001 vs. CMD+T3 and CS. Difference between CS and CMD+T3 is not 
significant. 
CS CMD CMD+T3 
0
20
40
60
80
100
120
140
CS CMD CMD + T3
Total liver 
triglycerides 
(mg/g liver)
  *** 
 - 51 - 
Successively, we sought an explanation for the serum and hepatic triglyceride-lowering 
effects of T3 by assessing the hepatic expression of genes involved in fatty acid 
turnover. We investigated if the prevention of hepatic steatosis by T3 depends on the 
ability of the liver to enhance fatty acid oxidation to get rid of the excess fatty acids. 
Although fatty acids can undergo oxidation via different mechanisms, most of them are 
degraded by means of β-oxidation, which occurs in both mitochondria and peroxisomes 
(Fig. 17). 
 
 
 
Fig. 17. Mitochondrial and peroxisomal β-oxidation systems (SCPx, sterol carrier 
protein x) (Reddy and Hashimoto, 2001). 
 
Mitochondrial β-oxidation, which results in shortening of fatty acids progressively into 
acetyl-CoA subunits, is primarily involved in the oxidation of the bulk of short-chain 
(<C8), medium-chain (C8-C12) and long-chain (C12-C20) fatty acids. Then, acetyl-CoA 
subunits either enter the tricarboxylic acid cycle (Krebs cycle) for further oxidation to 
water and carbon dioxide or condense to ketone bodies (acetoacetate, acetone, β-
hydroxybutyrate) in liver that serve as oxidizable energy substrates for extrahepatic 
tissues, especially during starvation (Reddy and Hashimoto, 2001). Mitochondrial β-
oxidation requires two steps: the first one is the transference of the acyl group from the 
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long chain fatty acid to carnitine and then the transport into the matrix; the second one 
is the intramitochondrial chain shortening consisting of a repeating circuit of four 
sequential reactions: 1) dehydrogenation; 2) hydration; 3) second dehydrogenation; 4) 
thiolytic cleavage (Serviddio et al., 2007). 
One of the major pathways leading to increased mitochondrial fatty acid oxidation 
involves activation of the rate-limiting enzyme, carnitine-palmitoyltransferase1A 
(CPT1A). CPT1A, the outer enzyme of the CPT system, converts long-chain fatty acyl-
CoAs to acylcarnitines for translocation across the mitochondrial membrane (Reddy and 
Rao, 2006). Therefore, being the mitochondrial gateway for fatty acids, CPT1A is the 
main controller of the hepatic β-oxidation flux (Serviddio et al., 2007). Jansen et al. 
(2000) have already shown that the thyroid hormone (T3) stimulates CPT1A 
transcription much more in the liver than in non-hepatic tissues. 
Mitochondrial β-oxidation is also rate-regulated by the mitochondrial trifunctional 
protein (MTP) complex which carries out the second, third and fourth β-oxidation steps 
(Fig. 17). MTP is a hetero-octomer made up of four α-subunits with long-chain enoyl-
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activities (MTP-α), and four β-
subunits with long-chain 3-oxo-/or keto-thiolase activity (MTP-β) (Reddy and 
Hashimoto, 2001). Analysis of the histopathological changes in the homozygous null 
mice for the α-subunit of MTP revealed that MTP-α
-/-
 mice develop hepatic steatosis 
immediately after birth and die suddenly 6-36 hours after birth (Ibdah et al., 2001). 
Partial oxidation, streamlined exclusively toward the metabolism of less abundant and 
relatively more toxic and biologically active very-long-chain fatty acids (containing 20 
or more carbon atoms, >C20), 2-methyl-branched fatty acids, dicarboxylic acids, 
prostanoids and C27 bile acid intermediates, occurs in peroxisomes. The presence of a 
fatty acid β-oxidation system in these cell organelles was described for the first time in 
glyoxysomes of germinating castor bean seedlings. Seven years later, a similar system, 
outside the mitochondrial compartment, was found in rat liver peroxisomes. Since then, 
it became evident that both mitochondrial and peroxisomal β-oxidation exist in the same 
cell. Despite being catalyzed by different enzymes encoded by different genes and 
having different roles, both pathways are functionally correlated (Reddy and 
Hashimoto, 2001). In fact, peroxisomal β-oxidation is preferentially involved in the 
chain shortening of very-long-chain fatty acids, and thus generating substrates for 
further completion of oxidation in mitochondria (Wanders, 2004). Distinctive 
differences between peroxisomal and mitochondrial oxidation pathways reflect the fact 
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that the first dehydrogenation of mitochondrial β-oxidation is replaced with an oxidation 
catalyzed by acyl-CoA oxidase (ACO), the rate-limiting enzyme of peroxisomal β-
oxidation, converting very-long-chain fatty acyl-CoAs to their corresponding trans-2-
enoyl-CoAs. This reaction results in the formation of H2O2 rather than NAD
+
 (Fig. 17) 
(Nguyen et al., 2008). It is of relevant importance to mention that mice with a disrupted 
ACO gene exhibit severe steatohepatitis (Fan et al., 1998). 
Therefore, the effect of T3 on the expression of genes involved in peroxisomal and 
mitochondrial fatty acid oxidation was evaluated. As far as peroxisomal β-oxidation is 
concerned, we observed that ACO mRNA expression levels in the liver were slightly 
lower in CMD rats compared to the CS diet-fed animals, whereas in the CMD+T3 diet-
fed rats ACO mRNA expression levels resulted strongly induced (Fig. 18). On the other 
hand, the mRNA levels of the key genes involved in mitochondrial β-oxidation: 
CPT1A, MTPα and MTPβ tended to be significantly higher in the CMD+T3-diet fed 
rats (Fig. 19). 
 
 
                                              CS      │   CMD  │  CMD+T3 
 
 
Fig. 18. Northern blot analysis of ACO mRNA levels. Total RNA from the liver of rats 
fed the CS, CMD or CMD+T3 diet for 1 week was prepared and analyzed as described 
in ‘‘Materials and Methods’’. 18S was used as a loading control. Each lane represents 
an individual sample. 
 
 
 
 
 
 
ACO 
18S 
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                                             CS     │     CMD    │  CMD+T3 
 
 
 
Fig. 19. Northern blot analysis of CPT1A, MTP-α and MTP-β mRNA levels. Total 
RNA from the liver of rats fed the CS, CMD or CMD+T3 diet for 1 week was prepared 
and analyzed as described in ‘‘Materials and Methods’’. 18S was used as a loading 
control. Each lane represents an individual sample. Below, densitometric quantification 
(
***
P<0.001 or 
*
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It is worth mentioning that our results are in line with the general conclusions obtained 
from studies on 3,5-diiodothyronine (T2), a product of a currently unknown peripheral 
enzymatic process, most probably utilizing T3 as its precursor, published by Lanni et al. 
in 2005. Their results show that T2 administration to rats receiving a high-fat diet 
(HFD) (when compared to rats receiving HFD alone) induces a complete disappearance 
of fat from the liver. This anti-steatotic effect of T2 is accompanied by significant 
reduction in the body weight, serum triglyceride, cholesterol levels, and an increased 
hepatic β-oxidation via an activation of the CPT system (Lanni et al., 2005; Moreno et 
al., 2008). Moreover, in another important study, Nagasawa et al. evaluated the effects 
of bezafibrate, a PPAR pan agonist, on the prevention of steatohepatitis in mice fed the 
CMD diet. Concurrent administration of the CMD diet and bezafibrate for 5 weeks 
resulted in reduction in the plasma ALT concentration, hepatic steatosis, products of 
lipid peroxidation and necro-inflammation. Similar to T3, bezafibrate increased the 
levels of hepatic mRNAs associated with fatty acid β-oxidation (acyl-CoA oxidase and 
carnitine palmitoyltransferase-1), but also reduced the levels of cytokines or 
transcription factors associated with inflammatory process [transforming growth factor-
β1 (TGF-β1), IL-6, IL-1β, monocyte chemoattractant protein-1 (MCP-1), tumour 
necrosis factor α (TNF-α) and nuclear factor κB1 (NF-κB1)] (Nagasawa et al., 2006). 
 
To further clarify the mechanism through which T3 rapidly prevented liver steatosis, we 
also examined the protein levels of L-FABP. 
Alternations in circulating FFAs are widely believed to play a key role in hepatic 
steatosis. As recently published, members of a conserved family of cytosolic lipid-
binding proteins known as fatty acid-binding proteins (FABPs), might contribute to 
disturbances in lipid homeostasis being involved in the complex and dynamic process of 
fatty-acid and other lipid trafficking (Chmurzyńska, 2006). Among the numerous 
functions proposed for FABPs, we can highlight transport facilitation of lipids to 
specific compartments in the cell, such as to the lipid droplets for storage; to the 
endoplasmic reticulum for signalling, trafficking and membrane synthesis; to the 
mitochondria or peroxisome for oxidation; to cytosolic or other enzymes to regulate 
their activity; and to the nucleus for the control of lipid-mediated transcriptional 
regulation. Since the discovery of FABPs in the early 1970s, at least 9 members have 
been identified. The family includes liver (L‑), intestinal (I‑), heart (H‑), adipocyte 
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(A‑), epidermal (E‑), ileal (Il‑), brain (B‑), myelin (M‑) and testis (T‑) FABPs. 
However, it should be underlined that no FABP is exclusively specific for a given cell 
type or tissue, and most tissues express several FABP isoforms (Furuhashi and 
Hotamisligil, 2008). 
The aim of our interest, L-FABP is expressed as an abundant gene product in 
differentiated enterocytes and hepatocytes, with lower levels of expression in the kidney 
and colon. Facilitating fatty acid transport and utilization, L-FABP reversibly binds a 
broad range of ligands, including fatty acids, with a preference for unsaturated versus 
saturated fatty acids, branched-chain fatty acids, cholesterol, and bile acids (Thompson 
et al., 1999; Storch and Thumser, 2000; Norris and Spector, 2002). In order to enhance 
the understanding of L-FABP functions and to study its impact on lipid metabolism, 
mice with a targeted deletion in the L-FABP gene were generated. As reported in the 
literature, Newberry et al. observed significantly less neutral lipid accumulation (~4-
fold lower hepatic TG content) in L-FABP
-/-
 mice in comparison to wild-type controls 
following an acute 48-hour fasting. Moreover, isolated hepatocytes from fasted L-
FABP
-/-
 mice demonstrated impaired incorporation of oleate into triglyceride and 
diacylglycerol (Newberry et al., 2003). It is noteworthy that in the following publication 
Newberry et al. also showed that L-FABP
-/-
 mice placed on a high-saturated fat, high-
cholesterol (0,15%) Western diet for up to 18 weeks are less obese and accumulate less 
hepatic triglyceride than C57BL/6J controls. The main observation of their study was 
that L-FABP may function as a metabolic sensor in regulating lipid homeostasis and 
therefore, protecting against Western diet-induced obesity and hepatic steatosis through 
a series of adaptations in both hepatic and extrahepatic energy substrate use. However, 
the precise mechanisms remain elusive (Newberry et al., 2006). 
Notably, in our experiment, feeding the CMD+T3 diet caused a strong reduction in the 
levels of L-FABP (Fig. 20). It could suggest that T3 prevents the CMD diet-induced 
fatty liver by reducing the transfer of fatty acids for glycerolipid biosynthesis. 
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                                              CS    │   CMD   │  CMD+T3 
 
 
Fig. 20. Changes in protein expression of L-FABP. Western blot analysis was 
performed as described in ‘‘Materials and Methods’’. Actin was used as loading 
control. 
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AIM 1b 
Effect of T3 on the reversal of fully established fatty liver 
 
 
To analyze whether feeding the CMD diet followed by feeding the CMD diet containing 
T3 could influence the reversal of CMD-induced fatty liver, we followed the 
experimental protocol III. First of all, a significant increase in liver weight and in the 
liver-to-body weight ratio (Table 5), accompanied by a decrease in serum TG levels and 
a 4-fold increase in the levels of ALTs was observed in rats fed the CMD-diet compared 
to animals fed the CS diet (Table 6). By contrast, T3 co-administration provoked a 
significant reduction in liver weight, liver-to-body weight ratio (Table 5) and serum 
transaminases (Table 6) compared to rats fed the CMD diet alone. A further decrease in 
the serum values of TGs was also observed (Table 6). 
 
 
Treatment 
 
Body Weight (g) 
 
Liver Weight (g) Liver-to-Body 
Weight Ratio (%) 
 
CS 
 
 
270 ± 0.1 
 
 
9.98 ± 0.2 
 
 
3.70 ± 0.06 
 
 
CMD 
 
 
284 ± 3.7 
*
 
 
 
12.08 ± 0.2 
***
 
 
 
4.25 ± 0.07 
***
 
 
 
CMD+T3 
 
 
255 ± 3.5 
###
 
 
 
8.92 ± 0.2 
###
 
 
 
3.49 ± 0.05 
###
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.005, 
###
P<0.001 vs. CMD 
 
Table 5. Effect of T3 on body weight, liver weight, liver-to-body weight ratio in rats fed 
the CMD diet for 11 weeks. Values are expressed as means ± SE of 5 to 6 animals per 
group. 
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Treatment 
 
TG (mg/dl) AST (U/L) ALT (U/L) 
 
CS 
 
 
282.3 ± 16 
 
 
147 ± 4.9 
 
 
43 ± 3.5 
 
 
CMD 
 
 
95.8 ± 6.2 
***
 
 
 
211 ± 18 
*
 
 
 
179 ± 10 
***
 
 
CMD+T3 
 
62.2 ± 4.0 
** ##
 
 
157 ± 9.3 
#
 
 
82 ± 6.8
* ###
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.005, 
###
P<0.001 vs. CMD 
 
Table 6. Effect of T3 on serum levels of TGs, ALTs and ASTs in rats fed the CMD diet 
for 11 weeks. Values are expressed as means ± SE of 5 to 6 animals per group. 
 
 
From a histological point of view, liver sections of the CMD diet-fed rats showed 
macrovesicular steatosis and numerous fatty droplets within hepatocytes when 
compared to the CS diet-fed animals. A completely different picture emerged in rats fed 
the CMD diet with T3. Liver histology showed neither steatosis nor inflammation (Fig. 
21). Having noted these changes, we examined whether the histological absence of 
steatosis in rats fed the CMD diet with T3 could be attributed to altered hepatic 
triglyceride handling. Determination of the hepatic TG content confirmed that feeding 
the CMD+T3 diet significantly lowered total hepatic triglyceride levels compared to the 
CMD diet-fed rats (Fig. 22). 
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Fig. 21. Photomicrographs showing hematoxylin-eosin stained sections of liver tissue 
from rats fed the CS or CMD diet for 11 weeks or CMD diet for 10 weeks followed by 
1 week of T3 co-feeding. Numerous fatty droplets within hepatocytes were observed in 
the liver from rats fed the CMD diet (original magnification x20). 
 
 
Fig. 22. Hepatic triglyceride content. Data is presented as means ± SE; 5 rats per group. 
***
P<0.001 vs. CMD+T3 and CS. Difference between CS and CMD+T3 is not 
significant. 
 
Recently, the group of Ip et al., after having previously shown that co-administration of 
the peroxisome proliferator-activated receptor α (PPARα) agonist, Wy-14,643, prevents 
the development of CMD diet-induced steatohepatitis, have tested whether this 
compound ameliorates established steatohepatitis. In accordance with our results, 
treatment with this fibrate significantly decreased ALT levels and reduced fat 
accumulation. They have also found that the reversal of CMD diet-induced hepatic 
inflammation was accompanied by the reduction of the number and activation of 
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hepatic macrophages, down-regulation of hepatic vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) mRNA levels, downstream 
targets of nuclear factor κB (NF-κB) activation (Ip et al., 2003; Ip et al., 2004). 
Therefore, there is a considerable interest in delineating the factors that initiate the onset 
of necro-inflammation. It is known that lipoperoxides are not only increased in areas of 
hepatic steatosis in human NASH but also accumulate in the livers of animals fed the 
CMD diet (Seki et al., 2002). Some of the end products of lipid peroxidation have 
proinflammatory properties and may play a crucial role in the pathogenesis of 
steatohepatitis mediating inflammatory recruitment directly [e.g. it was found that 4-
hydroxy-2-nonenal (4-HNE), the end product of lipid peroxidation, represents one of 
the inducers of COX-2 (Kumagai et al., 2000)] or indirectly by activating NF-κB with 
downstream consequences that include expression of adhesion molecules, cytokines 
(TNF-α, IL-1β, IL-6) and COX-2 (Leclercq et al., 2004; Yu et al., 2006). 
The cyclooxygenase (COX) enzyme (termed also prostaglandin H synthase) is known to 
catalyze the first step of the synthesis of prostanoids (including prostaglandins, 
thromboxanes, prostacyclins) by converting arachidonic acid into prostaglandin H2. In 
detail, COX is a bifunctional enzyme exhibiting both fatty acid COX activity 
(catalyzing the conversion of arachidonic acid to prostaglandin G2) and prostaglandin 
hydroperoxidase activity (catalyzing the conversion of prostaglandin G2 to 
prostaglandin H2). In the early 1990s, two distinct isoforms of COX were recognized. 
COX-1 is constitutively expressed as a ‘‘housekeeping’’ enzyme in most tissues and 
mediates physiological responses, including cytoprotection of the stomach and platelet 
aggregation. By contrast, COX-2, primarily responsible for the synthesis of the 
prostanoids involved in pathological processes (acute and chronic inflammatory states), 
is present in very low amounts and becomes rapidly induced by lipid peroxides, 
oxidative stress, NF-κB, cytokines (TNF-α, IL-1β, IL-6), and TGF-β1 (Hinz and Brune, 
2002). Recently, Yu et al. have reported that the temporal profile of increased COX-2 
expression in male C57BL/6N mice fed the CMD diet for five weeks paralleled the 
histological development of steatohepatitis. COX-2 up-regulation was preceded by 
activation of NF-κB and coincided with significantly elevated levels of TNF-α, IL-6 and 
ICAM-1. However, induction of COX-2, proposed as a pro-inflammatory mediator in 
steatohepatitis, resulted completely suppressed by dietary supplementation with the 
potent and specific PPAR-α agonist, Wy-14,643 (Yu et al., 2006). For this reason, we 
made an attempt to investigate the effect of T3 on COX-2 protein levels. The results 
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shown in Figure 23 demonstrate that COX-2 protein expression is increased in the CMD 
diet-fed animals when compared to the CS diet-fed rats, whereas the CMD+T3 diet-fed 
animals have the hepatic levels of this pro-inflammatory mediator strongly decreased. 
Strikingly up-regulated activity of cytochrome P450 (CYP) enzyme 2E1 has been 
documented as another important event promoting liver injury in a rat dietary model of 
steatohepatitis (Weltman et al., 1998). As proposed by Liu et al., CYP2E1-
overexpressing hepatocytes have both basal and TNF-α-induced increased levels of c-
Jun N-terminal kinase (JNK) activity (Liu et al., 2002). Members of the JNK family, 
also called stress-activated protein kinase (SAPK), subgroup of mitogen-activated 
protein kinases (MAP kinases), involved in proliferation, apoptosis, motility, 
metabolism and DNA repair, are known to be activated by diverse extracellular stimuli, 
including UV irradiation, pro-inflammatory cytokines and certain mitogens. 
Phosphorylation on invariant threonine and tyrosine residues, within a TXY motif in the 
activation loop, by dual specificity MAP kinase kinases (MAPKKs) is required for all 
MAP kinases activation (Minden et al., 1997). Dysregulated JNK signalling has been 
implicated in many diseases involving neurodegeneration, chronic inflammation, birth 
defects, cancer and ischemia/reperfusion injury (Johnson and Nakamura, 2007). 
Moreover, it has been reported that suppression of the JNK pathway in the liver 
decreases insulin resistance and markedly improves glucose tolerance in two different 
diabetic animal models (Nakatani et al., 2004). In the CMD diet-fed mice, activation of 
hepatic JNK, c-Jun, and AP-1 signalling occurs in parallel with the development of 
steatohepatitis (Schattenberg et al., 2006); therefore, the levels of active, 
phosphorylated JNK (phospho-SAPK/JNK) were examined in our experimental model 
of steatohepatitis. While very low activation of SAPK/JNK was observed in the non-
injured livers of CS diet-fed animals, increased levels of phosphorylated JNK were 
detected in CMD diet-fed animals. Co-feeding with T3 almost completely inhibited 
activation of this kinase (Fig. 23). 
Successively, we examined the effect of T3 on the hepatic levels of phosphorylated 
STAT 3, a member of the Janus kinase-signal transducers and activators of transcription 
(JAK-STAT) signalling pathway implicated in a bewildering complexity of cellular 
responses to cytokines and growth factors in the hematopoietic, immune, neuronal and 
hepatic systems (Turkson and Jove, 2000). In the liver, STAT 3, mainly activated by IL-
6 and its related cytokines (e.g. oncostatin M, cardiotrophin-1), and IL-22 plays a 
crucial role in the acute phase response, promotion of liver regeneration, inflammation, 
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glucose homeostasis, and hepatic lipid metabolism (Gao, 2005). STAT 3 has a 
conserved amino-terminal domain mediating the interaction between two STAT dimers 
to form a tetramer, a coiled-coil domain involved in interactions with regulatory 
proteins and other transcription factors, a DNA-binding domain making direct contact 
with STAT-binding sites in gene promoters, an SH2 domain required for STAT 
dimerization, and a carboxy-terminal transactivation domain; similarly to other STAT-
family members (Levy and Lee, 2002). This transcription factor is activated by tyrosine 
phosphorylation at a Tyr705, as well as by serine phosphorylation in the carboxy-
terminal transcriptional activation domain (Ser727). Tyrosine phosphorylation in 
response to cytokine stimulation is mediated by a Janus kinase (most often JAK1) and 
activates SH2-mediated dimerization rapidly followed by nuclear translocation. STAT 3 
dimers bind to interferon-γ-activated sequence (GAS) DNA element resulting in the 
transcriptional regulation of a wide range of target genes, such as: c-jun, c-myc, Jun B, 
cyclin D1, p21
WAF1/Cip1
, and acute-phase genes (Darnell Jr. et al., 1994; Gao, 2005). 
STAT 3 serine phosphorylation enhances its transcriptional activity and is required for 
maximal activation of its signalling (Turkson and Jove, 2000). Our studies have clearly 
shown that STAT 3 activation was significantly up-regulated in the liver of the CMD 
diet-fed animals compared to the CS diet-fed rats. In accordance with its suggested 
proinflammatory role (Suzuki et al., 2001; Lovato et al., 2003; Han et al., 2005; Mudter 
et al., 2005), hepatic protein levels of phosphorylated STAT 3 were strongly reduced in 
the livers of rats given the CMD+T3 diet, compared to the CMD diet-fed animals (Fig. 
23). 
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                                                    CS     │  CMD  │ CMD+T3 
 
 
Fig. 23. Hepatic SAPK/JNK, phospho-SAPK/JNK, STAT 3, phospho-STAT 3 and 
COX-2 protein levels determined by Western blot analysis (performed as described in 
‘‘Materials and Methods’’). Actin was used as a loading control. Each lane represents a 
single sample. 
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AIM 2a 
Effect of GC-1 on the prevention of CMD-induced fatty liver 
 
 
In our experiments, we saw that an excess of triiodothyronine can result in 
therapeutically desirable effects. At the same time, T3 is known to increase heart rate, 
speed and force of systolic contraction, shorten the duration of diastolic relaxation and 
affect vascular tone (Trost et al., 2000). Therefore, the primary aim of this experiment 
was to investigate if the beneficial effect of T3 on liver steatosis and steatohepatitis 
might be achieved by GC-1, a TRβ-selective agonist, administration without inducing a 
thyrotoxic state. 
Consequently, we used the experimental protocol IV. Rats were fed the CS, CMD or 
CMD diet supplemented with 5 mg/kg of GC-1 for 2 weeks. In all experimental groups, 
no differences in physical activity and behaviour were observed. Moreover, appearance 
of animals remained healthy. Similar to the effect of T3, co-administration of GC-1 for 
2 weeks provoked significant weight loss, reduced liver-to-body weight ratio and serum 
TG levels (Table 7, 8). As expected, within 14 days of CMD+GC-1 exposure, serum 
levels of ALTs and ASTs were also diminished (Table 8). 
 
Treatment 
 
Body Weight (g) 
 
Liver Weight (g) Liver-to-Body 
Weight Ratio (%) 
 
CS 
 
 
155 ± 2.9 
 
 
7.28 ± 0.17 
 
 
4.69 ± 0.04  
 
CMD 
 
 
149 ± 3.3 
 
 
11.42 ± 0.36 
***
 
 
 
7.66 ± 0.16 
***
 
 
CMD+GC-1 
 
 
136 ± 2.5 
** #
 
 
 
6.83 ± 0.30 
###
 
 
 
5.02 ± 0.21 
###
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.01, 
###
P<0.001 vs. CMD 
 
Table 7. Effect of GC-1 on body weight, liver weight, liver-to-body weight ratio in rats 
fed the CMD diet for 2 weeks. Values are expressed as means ± SE of 5 to 6 animals 
per group. 
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Treatment 
 
TG (mg/dl) AST (U/L) ALT (U/L) 
 
CS 
 
 
162 ± 13 
 
 
73 ± 4 
 
 
124 ± 6 
 
 
CMD 
 
 
85 ± 10 
***
 
 
 
174 ± 17 
**
 
 
 
197 ± 12 
**
 
 
 
CMD+GC-1 
 
 
53 ± 3 
*** #
 
 
134 ± 10 
* #
 
 
 
168 ± 9 
* #
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.01, 
###
P<0.001 vs. CMD 
 
Table 8. Effect of GC-1 on serum levels of TGs, ALTs and ASTs in rats fed the CMD 
diet for 2 weeks. Values are expressed as means ± SE of 5 to 6 animals per group. 
 
Furthermore, CMD diet-fed rats developed macrovesicular steatosis, whereas in the 
CMD+GC-1 group histological analysis revealed minimal steatosis. No steatosis was 
observed in zone 1 and 2 of the liver acinus except the periportal areas where lipid 
droplets were still present (Fig. 24). To further validate histological differences in the 
presence of steatosis, hepatic triglyceride content was determined (Fig. 25). Similar to 
T3, GC-1 caused a reduction of the CMD-induced TG accumulation in the liver. 
However, TRβ-selective agonist exerted a weaker effect than T3 in reduction of hepatic 
TG content. 
 
 
 
Fig. 24. Representative histology of liver tissue. Hematoxylin-eosin staining of liver 
sections from rats fed the CS, CMD and CMD+GC-1 diet for 2 weeks (original 
magnification x20). 
CMD CMD+GC-1 CS 
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Fig. 25. Hepatic triglyceride content. Values are expressed as means ± SE; 5 rats per 
group. 
***
P<0.001 vs. CMD+GC-1 and CS. Difference between CS and CMD+GC-1 is 
not significant. 
 
A satisfactory unifying mechanism explaining the causes leading to steatohepatitis has 
been sought for many years. The most frequently posed question was why some patients 
with steatosis, regardless of etiology, never develop progressive liver disease. An 
enormous number of reports in the literature led to the identification of oxidative stress 
as a factor involved in the pathogenesis of steatosis and steatohepatitis. A milestone, 
which provided a pathophysiologic rationale for the progression of NAFLD, was the 
‘‘two-hit’’ theory launched by Day and James in 1998. According to this model (Fig. 
26), the initial insult or ‘‘first hit’’ is represented by hepatic steatosis, a prerequisite for 
subsequent events that lead to liver injury. Liver becomes susceptible to secondary 
insults, however, the disease does not progress unless additional cellular events occur. 
The presence of some other factor(s)-‘‘second hit’’ is required for the development of 
steatohepatitis. The ‘‘second hit’’, stated as a central biochemical mechanism of 
hepatocellular injury in NASH, can be represented by free radicals capable of inducing 
imbalance between pro-oxidant and antioxidant chemical species (oxidative stress) (Day 
and James, 1998). 
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Fig. 26. The ‘‘two hit’’ hypothesis for the pathogenesis of non-alcoholic steatohepatitis 
(Koteish and Diehl, 2002). 
 
In the physiological state cytochrome P450, peroxisomal β-oxidation and mitochondrial 
electron leak are 3 possible sites at which pro-oxidant ROS can be generated. In 
particular, strikingly up-regulated activity of cytochrome P450 (CYP) enzyme 2E1, 
known to form active oxygen species (superoxide anions, hydroxyl radicals, hydrogen 
peroxides) during microsomal ω-oxidation, has been documented in the fatty liver 
(Weltman et al., 1998; Robertson et al., 2001). There is also accumulating evidence that 
in an environment enriched with lipids, mitochondrial dysfunction (hampering electron 
transfer within the respiratory chain) lead to an overproduction of ROS (Kass, 2006; 
Serviddio et al., 2007). 
A consequence of significantly increased ROS generation includes damage of 
membranes via lipid peroxidation. The process of lipid peroxidation, leading to 
oxidative destruction of polyunsaturated fatty acids (PUFAs), integral of cellular 
membranes, is initiated by the attack on a fatty acid or fatty acyl side chain of any 
chemical species having sufficient reactivity to abstract a hydrogen atom from a 
methylene carbon in the side chain. In living cells, reactive oxygen species (such as 
OH·) have the potential to cause initiation of lipid peroxidation. The greater the number 
of double bonds in a fatty acid side chain, the easier is the removal of a hydrogen atom. 
Therefore, PUFAs are readily attacked by free radicals and particularly susceptible to 
peroxidation. The hydrogen atom has a single electron and its removal leaves behind an 
unpaired electron on the carbon atom to which it was originally attached. The resulting 
fatty acid radical usually undergoes molecular rearrangement, followed by reaction with 
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molecular oxygen creating a peroxyl radical. Then, peroxyl radicals can react with each 
other propagating the chain reaction of lipid peroxidation or abstract hydrogen from 
adjacent fatty acid side chains producing a lipid hydroperoxide (Halliwell and Chirico, 
1993). Lipid hydroperoxides breakdown in biological systems forms a great diversity of 
aldehydes. The most abundant are malondialdehyde (MDA) and 4-hydroxyalkenals (4-
HDA), in particular 4-hydroxy-2-nonenal (4-HNE) (Esterbauer and Cheeseman, 1990). 
First of all, lipid peroxidation products can damage the mitochondrial genome, which is 
particularly prone to oxidative stress. Although nuclear DNA encodes most respiratory 
chain polypeptides, 13 polypeptides are encoded by mitochondrial DNA (mtDNA). 
Thus, mtDNA damage can secondarily impair electron transfer in the respiratory chain. 
Secondly, some lipid peroxidation products are potent inducers of mitochondrial 
permeability transition (MPT) that can lead to cell death (Begriche et al., 2006). Lastly, 
reactive lipid peroxidation products have the potential to diffuse from their site of origin 
to reach distant intracellular and extracellular targets, thereby amplifying the oxidative 
stress that led to their initial formation (Neuschwander-Tetri et al., 2003b; Browning 
and Horton, 2004). In addition, the aldehyde products, 4-hydroxyalkenals and 
malondialdehyde (MDA), are known to be capable of activating hepatic stellate cells 
and contribute to inflammation by activating NF-κB. This transcription factor regulates 
the expression of several proinflammatory cytokines and adhesion molecules (TNF-α, 
IL-8, E-selectin) (Diehl et al., 2005; Choi and Diehl, 2008). 
The CMD-diet model is recognised as a very reproducible pattern of lipid peroxidation 
in the liver and offers a perspective in the exploration of the role of free radicals in fat 
accumulation. Accumulating evidence that oxidative stress and lipid peroxidation are 
the most pathogenic mechanisms of non-alcoholic fatty liver disease, led us to examine 
this issue. 
To avoid misleading results, great importance on the reliable assessment of lipid 
peroxidation should be placed (Esterbauer et al., 1991). Even if many assays are 
available to measure lipid peroxidation, determination of the sum of malondialdehyde 
and 4-hydroxyalkenals has been widely used as a convenient indicator of lipid 
peroxidation (Esterbauer and Cheeseman, 1990). For this purpose, the TBA 
(tiobarbituric acid) test, probably because of its simplicity and cheapness, is one of the 
most commonly applied assays. In the sample under test one molecule of MDA reacts 
with two molecules of TBA with the production of a pink chromogen having an 
absorption maximum at 532-535 nm (Janero, 1990). However, it is well documented 
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that the TBA test application to body fluids and tissue extracts can produce a host of 
problems. First, this test is intrinsically nonspecific for MDA and aldehydes other than 
MDA can form chromogens with absorbance at 532 nm. Second, it rarely measures the 
free MDA content of the lipid system. Most, if not all, of the MDA measured is 
generated by decomposition of lipid peroxides during the acid heating stage of the test. 
Third, peroxide decomposition produces radicals that can start peroxidation of other 
lipid molecules during the assay, amplifying the response. In conclusion, the TBA assay 
is strongly influenced by the reaction conditions (Halliwell and Chirico, 1993). 
As a consequence, for our study, we used a colorimetric assay for lipid peroxidation 
developed by Gérard-Monnier et al. in 1998. The Bioxytech
®
 LPO-586 kit
TM
 is based 
on the reaction of a chromogenic reagent, N-methyl-2-phenylindole, with MDA and 4-
HDA. Under mild-temperature conditions, using a methanesulfonic acid-based medium, 
one molecule of either MDA or 4-HDA reacts with 2 molecules of N-methyl-2-
phenylindole, to yield a stable chromophore with intense maximal absorbance at 586 
nm. 
In this experiment, measurement of hepatic lipoperoxides revealed that in the CMD 
diet-fed rats lipid peroxidation was increased compared to those fed the control diet. It 
was important to note that administration of the CMD diet with GC-1 significantly 
diminished lipoperoxidation compared to rats fed the CMD diet alone (Fig. 27). 
 
 
Fig. 27. Histogram demonstrating LPO levels. 
**
P<0.01 vs. CMD+GC-1 and CS. 
Difference between CS and CMD+GC-1 groups is not significant. 
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AIM 2b 
Effect of GC-1 on the reversal of fully established fatty liver 
 
 
The final experiment was performed to investigate if the severity of fully established 
fatty change could be reverted by feeding the CMD diet containing GC-1. To examine 
this potential capacity of GC-1 we followed the experimental protocol V. As expected, 
a significant increase in liver weight and in the liver-to-body weight ratio was observed 
in rats fed the CMD-diet (Table 9). This coincided with a decrease in serum TG levels 
and an increase in the levels of ALTs and ASTs (Table 10). GC-1 co-administration 
caused a decrease in both liver weight and liver-to-body weight ratio and a decrease in 
the serum values of TGs compared to rats fed the CMD diet alone (Table 9, 10). The 
significant reduction of AST and ALT levels was also observed in the CMD+GC-1 diet-
fed rats (Table 10). 
Histological analyses of liver sections confirmed that rats fed the CMD diet for 12 
weeks developed severe macrovesicular steatosis. Successively, the fat pattern was 
observed in the CMD+GC-1 diet-fed animals for 14 days, following a 10-week CMD 
diet feeding. In addition, while the CMD+GC-1 feeding, 3- and 7-day intermediate time 
points were added in order to be able to observe the preceding effect of the 14-day 
treatment. Representative photomicrographs of hematoxylin-eosin-stained liver sections 
(Fig. 28) show that after only 3 days of treatment, GC-1 co-feeding caused a reduction 
in hepatic steatosis. This effect was even more evident after 7 days of treatment and 
almost complete disappearance of hepatic steatosis (very few small droplets were 
present) after 14 days was observed (Fig. 28). Consistent with the histological findings, 
7- and 14-day treatment with CMD+GC-1 significantly (P<0.001) reduced hepatic 
triglyceride content compared to CMD diet-fed rats (Fig. 29). To assess the impact of 
GC-1, hepatic lipoperoxide levels were measured. As expected, the disappearance of 
hepatic TGs was accompanied by a concomitant decrease of MDA and 4-HDA levels 
(Fig. 30). 
 
 
 
 
 - 72 - 
Treatment 
 
Body Weight (g) 
 
Liver Weight (g) Liver-to-Body 
Weight Ratio (%) 
 
CS 
 
 
297 ± 6.7 
 
 
10.63 ± 0.27 
 
 
3.58 ± 0.07 
 
 
CMD 
 
 
282 ± 1.2 
 
15.05 ± 0.13 
***
 
 
 
5.34 ± 0.03 
***
 
 
 
CMD+GC-1 
 
 
255 ± 4.8 
*** ##
 
 
9.20 ± 0.36 
###
 
 
 
3.60 ± 0.08 
###
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.01, 
###
P<0.001 vs. CMD 
 
Table 9. Effect of GC-1 on body weight, liver weight, liver-to-body weight ratio in rats 
fed the CMD diet for 12 weeks. Values are expressed as means ± SE of 5 to 6 animals 
per group. 
 
 
Treatment 
 
TG (mg/dl) AST (U/L) ALT (U/L) 
 
CS 
 
 
204 ± 25 
 
 
34 ± 6 
 
43 ± 5 
 
CMD 
 
 
36 ± 2 
***
 
 
 
279 ± 11 
***
 
 
 
248 ± 13 
***
 
 
 
CMD+GC-1 
 
 
47 ± 2 
###
 
 
159 ± 11 
*** ##
 
 
194 ± 13 
* #
 
 
 
*
P<0.05, 
**
P<0.005, 
***
P<0.001 vs. CS 
#
P<0.05, 
##
P<0.01, 
###
P<0.001 vs. CMD 
 
Table 10. Effect of GC-1 on serum levels of TGs, ALTs and ASTs in rats fed the CMD 
diet for 12 weeks. Values are expressed as means ± SE of 5 to 6 animals per group. 
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Fig. 28. Representative histology of liver tissue. Hematoxylin-eosin stained liver 
sections from rats fed the CS or CMD diet for 12 weeks or CMD diet for 10 weeks 
followed by 3, 7, and 14 days of CMD+GC-1 co-feeding (original magnification x20). 
 
 
Fig. 29. Hepatic triglyceride content. Data is expressed as means ± SE; 5 rats per group. 
***
P<0.001 vs. CMD. 
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Fig. 30. Hepatic lipoperoxide levels. 
*
P<0.05 vs. CMD+GC-1 and CS. 
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AIM 3 
Application of a metabolomic technique in order to analyse the liver lipid 
profile changes during treatment with GC-1 
 
 
Metabolites are known to be involved as key regulators of systems homeostasis (Mattila 
et al., 2008). Metabolic profiling (metabolomics), developed to an accepted and 
valuable tool in life sciences, is the measurement in biological systems of the 
complement of low-molecular-weight metabolites and their intermediates that reflects 
the dynamic response to genetic modification and physiological, pathophysiological, 
and/or developmental stimuli (Nicholson et al., 1999; Clarke and Haselden, 2008). In 
analogy to the genome, which is used as synonym for the entirety of all genetic 
information, the metabolome represents the entirety of the metabolites within a 
biological system (Oldiges et al., 2007). 
In recent years, lipidomics or lipid profiling (an extension of metabolomics), which 
measures the lipid complement of a cell, tissue or organism, has caught scientists’ 
attention as a research tool and become an important target of the postgenomic 
revolution (Roberts et al., 2008). The importance of the lipidomic analysis is 
considerable, knowing that, the disruption of lipid metabolic pathways accompanies 
many pathological states (e.g. cancer, diabetes, as well as neurodegenerative and 
infectious diseases) (Yetukuri et al., 2007). The rapid development in the areas of mass 
spectrometry (MS) and chromatography have led to significant advances within the 
field of lipidomics and liquid chromatography (LC)-MS has increasingly occupied an 
important position in the lipidomic methodologies (Plumb et al., 2003; Villas-Bôas et 
al., 2005; Roberts et al., 2008). This powerful technique combines the physical 
separation capabilities of LC with the mass analysis capabilities of MS. Unlike gas 
chromatography (GC)-MS, LC-MS seems to be a more versatile analytical method as it 
covers much wider mass range and does not require derivatization (Xie et al., 2008). 
Recently, a technique defined as ultra-performance liquid chromatography-mass 
spectrometry (UPLC-MS) has risen as a new category of analytical separation 
representing an improvement in chromatographic performance due to the evolution of 
packing materials used to effect the separation. According to the Van Deemter equation, 
which is particularly important in column design, as the particle size decreases to less 
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than 2.5 µm, there is a significant gain in chromatographic efficiency. Therefore, the use 
of sub-2 µm particles in UPLC, while reducing run times, improved the peak capacity 
(maximal number of resolved peaks that fit in a chromatogram), resulting in greater 
differentiation among peaks, as well as sensitivity because chromatographic bands 
appear more concentrated and elute as sharper peaks (Swartz, 2005). Coupled to 
quadrupole time-of-flight mass spectrometry (QTOF-MS) which delivers accurate mass 
identification, UPLC-QTOF-MS is increasingly being used for reliable lipid profiling 
(Beattie et al., 2005). 
Therefore, for our study, we employed the UPLC-QTOF-MS technique to observe 
major changes in the liver lipid profile. This metabolomic approach was applied to rats 
fed the CS or CMD diet for 12 weeks or CMD diet for 10 weeks followed by 3, 7, and 
14 days of CMD+GC-1 co-feeding (see the experimental protocol V). Moreover, the 
fourth group of rats fed rodent standard diet (a nutritionally balanced diet based on the 
growth criteria of the utilized species, on the contrary of the hyperlipidic CS diet) for 12 
weeks was added. 
Retention time (the time between sample injection and an analyte peak reaching a 
detector at the end of the column) and mass-to-charge ratio (m/z) data pairs used as the 
identifier of each detected peak from UPLC-QTOF-MS analysis were pre-processed 
and aligned employing XCMS, as shown in Figure 31. 
 
 
 
Fig. 31. Chromatographic alignment (XCMS). Sample profiles are coloured using a 
rainbow based on the order in which they were run, with red first and violet last. 
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The resulting matrix of retention corrected peak groups was further exported into 
SIMCA-P software for multivariate statistical analysis. Application of multivariate 
analysis to UPLC-MS data, pioneered by Nicholson et al. in 1999, facilitated accurate 
discrimination of the experimental groups. It should be mentioned that pattern 
recognition techniques are divided into unsupervised approaches where class 
membership is not known (e.g. principal components analysis-PCA), and supervised 
approaches where class membership is used to maximise the separation of data into 
distinct clusters (e.g. Partial Least Squares-Discriminant Analysis-PLS-DA) (Griffin, 
2006a, b). In our study, we employed both PCA and PLS-DA pattern recognition. 
To achieve the natural interrelationship including clustering and outliers without a 
priori knowledge of the data set, we applied PCA. As evident from Figure 32, the PCA 
scores plot exhibited a clear clustering of 3 distinct groups of rats fed the CMD, 
CMD+GC-1 and CS/standard diet. Additionally, the supervised PLS-DA model 
generated a more perfect differentiation ability among these 3 groups. The explained 
variation (R
2
) and predicted variation (Q
2
) helped to evaluate the quality of both 
models, indicating their reliability. To further improve this separation, PLS-DA pattern 
recognition was applied to the spectral data set only from tissue extracts of CS and 
standard-diet fed animals demonstrating differences in the lipid profile in these two 
groups. PLS-DA scores plot recapitulated in Figure 33 shows an apparent clustering of 
2 distinct groups of rats fed the CS or standard diet. 
 
 
Fig. 32. Resulting PCA and PLS-DA scores plot from UPLC-QTOF-MS data sets. The 
quality of the models was evaluated with the relevant R
2
 and Q
2
. 
R2X=0.689   Q2=0.557   A=3 
PCA PLS-DA 
CMD CMD+GC-1 CS Standard diet 
R2X=0.771   Q2=0.60   A=3 
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         PLS-DA 
 
 
Fig. 33. PLS-DA scores plot from UPLC-QTOF-MS data sets. The quality of the model 
was evaluated with the relevant R
2
 and Q
2
. 
 
Successively, metabolomics analysis allowed us to monitor the metabolite comparison 
between the CMD and CMD+GC-1 diet-fed animals. As demonstrated in Figure 34, the 
PCA scores plot of the CMD+GC-1- and CMD diet-fed rats suggests that the lipid 
content after 3 days of CMD+GC-1 treatment is similar to that of the CMD diet-fed 
animals and requires 7 to 14 days to stabilize. The quality of the model assessed with 
the relevant R
2
 and Q
2
 results good. Therefore, metabolomic analyses result consistent 
with previously discussed biochemical triglyceride measurement (Fig. 35). 
 
 
 
R2X=0.694   Q2=0.57   A=3 
 
 
Fig. 34. Resulting PCA scores plot from UPLC-QTOF-MS data sets. The quality of the 
model was evaluated with the relevant R
2
 and Q
2
. 
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Fig. 35. Liver triglyceride content in rats fed the CS or CMD diet for 12 weeks or CMD 
diet for 10 weeks followed by 3, 7, and 14 days of CMD+GC-1 co-feeding. 
 
In summary, the highly sensitive technique UPLC-QTOF-MS facilitates the 
achievement of an accurate picture of the changes in the lipid profile of the liver. The 
UPLC-QTOF-MS-based methodology went deeper than the histological and 
biochemical examinations, giving a clear evidence that CS and CMD+GC-1 (despite the 
absence of fat accumulation) lipid profiles are not superimposed. Moreover, a major 
advantage of the UPLC-MS technique is the ability to separate lipids from complex 
biological fluids into individual lipid categories (fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, 
polyketides) and/or within the same category into distinct classes and subclasses, which 
successively can be identified by searching spectral databases (Fahy et al., 2005). 
Although, in our study, we did not take advantage of this possibility, this approach may 
allow a comprehensive analysis of lipid molecules and further elucidate differences in 
the lipid profile. Taking into consideration the complexity of lipid categories, this 
analytical method affords screening of many lipid molecular species surpassing 
traditional lipid biochemistry. For example, in a recent study by Yetukuri et al., the 
UPLC-MS-based lipodomic characterisation of the fatty liver of the genetically obese 
insulin resistant ob/ob mice showed increased deposition of short chain tri- and di-
acylgycerol species and diacylphosphoglycerols associated with proportional increase 
of reactive ceramide lipid species, as well as down-regulation of sphingomyelins, the 
substrate for ceramide synthesis (Yetukuri et al., 2007). 
Finally, another important challenge in the metabolomic area is related to the future 
studies in identifying specific changes (biomarkers) in lipid composition at very early 
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stages of hepatic steatosis using the plasma. The metabolomic approach could also lead 
to the development of non-invasive techniques in order to replace liver biopsy. 
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CONCLUSION REMARKS 
 
 
Non-alcoholic steatohepatitis (NASH) is one of the most common forms of liver disease 
encountered in Western society. The present study is the first to evaluate the effects of 
T3 and GC-1, a TRβ-selective agonist, on fatty liver and steatohepatitis induced in rats 
fed a choline-deficient, methionine-restricted (CMD) diet. This model results in changes 
in the liver similar to those observed in human NASH. 
Viewed together, we observed that triiodothyronine exerts a strong inhibitory effect on 
the development of steatosis. Moreover, we found that the vastly increased expression 
of genes involved in peroxisomal and mitochondrial β-oxidation, as well as a decrease 
in the protein expression of L-FABP most likely account for reduced hepatic 
triglyceride content and prevention of hepatic steatosis. T3 also caused a rapid 
regression of fully established steatosis. This view was strengthened by dramatically 
reduced expression of COX-2, down-regulation of phospho-STAT 3 and JNK 
pathways, usually activated in inflammatory processes, as well as accompanied by a 
significant reduction of serum transaminases. We also noted that GC-1, a synthetic 
analog of thyroid hormone, selective for both binding and activation functions of TRβ1 
over TRα1, shares the capability of T3 to prevent and reverse steatosis. Devoid of 
thyrotoxic effects, GC-1 represents potentially valuable therapeutic advance as an agent 
for the treatment of liver damage with the possible relevance of the results of this study 
to humans. 
The initial results obtained with UPLC-QTOF-MS showed that this highly sensitive 
technique facilitates the achievement of an accurate picture of the changes in the liver 
lipid profile with relevance to the future studies in identifying specific changes in lipid 
composition at very early stages of hepatic steatosis using the plasma. The metabolomic 
approach could also lead to the development of non-invasive techniques in order to 
replace liver biopsy. 
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